<div id="displayContant">
<br><div class="long-title">
<span>Viekira Pak</span><span> (
					Dasabuvir and Ombitasvir and Paritaprevir and Ritonavir
				)</span>
</div>
<br><div class="section"><div id="VIEKIRA_PAK_collapsableElement_48780-1" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"></div></div></div>
<div class="section"><div id="VIEKIRA_PAK_collapsableElement_43683-2" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"><text>
                        <table id="t397211029" border="0" frame="void" rules="none">
                           <colgroup>
                              <col width="88%">
                              <col width="12%">
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td>Indications and Usage, Removed-Limitations of Use (<a href="#section_1">1</a>)</td>
                                 <td align="right">10/2015</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration, Testing Prior to Initiation of VIEKIRA PAK (<a href="#section_2.1">2.1</a>)</td>
                                 <td align="right">10/2015</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration, Recommended Dosage in Adults (<a href="#section_2.2">2.2</a>) </td>
                                 <td align="right">10/2015</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration, Hepatic Impairment (<a href="#section_2.4">2.4</a>)</td>
                                 <td align="right">10/2015</td>
                              </tr>
                              <tr>
                                 <td>Contraindications (<a href="#section_4">4</a>)</td>
                                 <td align="right">10/2015</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions (<a href="#section_5.1">5.1</a>)</td>
                                 <td align="right">10/2015</td>
                              </tr>
                           </tbody>
                        </table>
                     </text></div></div></div>
<div class="section">
<div id="nonCollapsableElement_34067-9">
<div class="drugSubheadings">
<span id="VIEKIRA_PAK_34067-9" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>1 INDICATIONS AND USAGE</div>
<div id="VIEKIRA_PAK_previewText_34067-9" class="previewText">
                  VIEKIRA PAK with or without ribavirin is indicated for the tr
                        VIEKIRA PAK with or without ribavirin is indicated for <span>...</span>
</div>
</div>
<div id="VIEKIRA_PAK_collapsableElement_34067-9" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText">
<text>
                  <p id="p004">VIEKIRA PAK with or without ribavirin is indicated for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis.</p>
               </text><text>
                        <p id="p417395291445208189">VIEKIRA PAK with or without ribavirin is indicated for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis. VIEKIRA PAK includes ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor. (<a href="#section_1">1</a>)</p>
                     </text>
</div></div>
</div>
<div class="section">
<div id="nonCollapsableElement_34068-7">
<div class="drugSubheadings">
<span id="VIEKIRA_PAK_34068-7" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>2 DOSAGE AND ADMINISTRATION</div>
<div id="VIEKIRA_PAK_previewText_34068-7" class="previewText">
                        Testing Prior to Initiation - Assess for laboratory and<span>...</span>
</div>
</div>
<div id="VIEKIRA_PAK_collapsableElement_34068-7" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                        <p id="p540164291445206843">Testing Prior to Initiation - Assess for laboratory and clinical evidence of hepatic decompensation. (<a href="#section_2.1">2.1</a>)</p>
                        <p id="p412324291444932873">Recommended dosage: Two ombitasvir, paritaprevir, ritonavir 12.5/75/50 mg tablets once daily (in the morning) and one dasabuvir 250 mg tablet twice daily (morning and evening) with a meal without regard to fat or calorie content. (<a href="#section_2.1">2.1</a>)</p>
                        <table id="t10527429" border="1" cellpadding="6" frame="box" width="100%">
                           <caption>Treatment Regimen and Duration by Patient Population</caption>
                           <colgroup align="center">
                              <col>
                              <col>
                              <col>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td stylecode="Rrule Botrule" align="center">
                                    <content stylecode="bold">Patient Population</content>
                                 </td>
                                 <td stylecode="Rrule Botrule" align="center">
                                    <content stylecode="bold">Treatment*</content>
                                 </td>
                                 <td stylecode="Botrule" align="center">
                                    <content stylecode="bold">Duration</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Botrule" align="center">
                                    <content stylecode="bold">Genotype 1a,</content>
                                    <br>
                                    <content stylecode="bold">without cirrhosis</content>
                                 </td>
                                 <td stylecode="Rrule Botrule" align="center">VIEKIRA PAK + ribavirin</td>
                                 <td stylecode="Botrule" align="center">12 weeks</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Botrule" align="center">
                                    <content stylecode="bold">Genotype 1a,</content>
                                    <br>
                                    <content stylecode="bold">with cirrhosis </content>
                                 </td>
                                 <td stylecode="Rrule Botrule" align="center">VIEKIRA PAK + ribavirin </td>
                                 <td stylecode="Botrule" align="center">24 weeks**  </td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Botrule" align="center">
                                    <content stylecode="bold">Genotype 1b,</content>
                                    <br>
                                    <content stylecode="bold">without cirrhosis</content>
                                 </td>
                                 <td stylecode="Rrule Botrule" align="center">VIEKIRA PAK</td>
                                 <td stylecode="Botrule" align="center">12 weeks</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Botrule" align="center">
                                    <content stylecode="bold">Genotype 1b,</content>
                                    <br>
                                    <content stylecode="bold">with cirrhosis</content>
                                 </td>
                                 <td stylecode="Rrule Botrule">VIEKIRA PAK + ribavirin</td>
                                 <td stylecode="Botrule" align="center">12 weeks</td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left">*Note: Follow the genotype 1a dosing recommendations in patients with an unknown genotype 1 subtype or with mixed genotype 1 infection.<br>**VIEKIRA PAK administered with ribavirin for 12 weeks may be considered for some patients based on prior treatment history <content stylecode="italics">[See Clinical Studies (<a href="#section_14.3">14.3</a>)]</content>.</td>
                              </tr>
                           </tbody>
                        </table>
                        <ul ultype="unordered" id="l4021492321417654502" stylecode="Disc">
                           <li>HCV/HIV-1 co-infection: For patients with HCV/HIV-1 co-infection, follow the dosage recommendations in the table above. (<a href="#section_2.1">2.1</a>)</li>
                           <li>Liver Transplant Recipients: In liver transplant recipients with normal hepatic function and mild fibrosis (Metavir fibrosis score ≤2), the recommended duration of VIEKIRA PAK with ribavirin is 24 weeks. (<a href="#section_2.3">2.3</a>)</li>
                        </ul>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_2_1" class="safetySubheading">2.1 Testing Prior to Initiation of VIEKIRA PAK</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p414865291444934784">
                           <content stylecode="xmChange">Prior to initiation of VIEKIRA PAK, assess for laboratory and clinical evidence of hepatic decompensation <content stylecode="italics">[see Warnings and Precautions (<a href="#section_5.1">5.1</a> and <a href="#section_5.2">5.2</a>)]</content>
                           </content>.</p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_2_2" class="safetySubheading">2.2 Recommended Dosage in Adults</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p77176241371236095">VIEKIRA PAK is ombitasvir, paritaprevir, ritonavir fixed dose combination tablets copackaged with dasabuvir tablets.</p>
                        <p id="p871710291393270971">The recommended oral dosage of VIEKIRA PAK is two ombitasvir, paritaprevir, ritonavir tablets once daily (in the morning) and one dasabuvir tablet twice daily (morning and evening). Take VIEKIRA PAK with a meal without regard to fat or calorie content<content stylecode="italics"> [see Clinical Pharmacology (<a href="#section_12.3">12.3</a>)]</content>.</p>
                        <p id="p399426291415738037">VIEKIRA PAK is used in combination with ribavirin (RBV) in certain patient populations (see <a href="#table_1">Table 1</a>). <content stylecode="xmChange"> When administered with VIEKIRA PAK, the recommended dosage of RBV is based on weight: 1000 mg/day for subjects &lt;75 kg and 1200 mg/day for those ≥75 kg, divided and administered twice-daily with food.</content> For ribavirin dosage modifications, refer to the ribavirin prescribing information.</p>
                        <p id="p397125291415738073">For patients with HCV/HIV-1 co-infection, follow the dosage recommendations in <a href="#table_1">Table 1</a>. Refer to <content stylecode="italics">Drug Interactions (<a href="#section_7">7</a>)</content> for dosage recommendations for concomitant HIV-1 antiviral drugs. </p>
                        <p id="p2883291393271102">
                           <a href="#table_1">Table 1</a> shows the recommended VIEKIRA PAK treatment regimen and duration based on patient population.</p>
                        <table id="table_1" border="1" frame="box" rules="all" width="100%">
                           <caption>Table 1. Treatment Regimen and Duration by Patient Population (Treatment-Naïve or Interferon-Experienced)</caption>
                           <colgroup>
                              <col width="33%">
                              <col width="33%">
                              <col width="33%">
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td stylecode="Rrule Botrule" align="center">
                                    <content stylecode="bold">Patient Population</content>
                                 </td>
                                 <td stylecode="Rrule Botrule" align="center">
                                    <content stylecode="bold">Treatment*</content>
                                 </td>
                                 <td stylecode="Botrule" align="center">
                                    <content stylecode="bold">Duration</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Botrule" align="center">
                                    <content stylecode="bold">Genotype 1a,</content>
                                    <br>
                                    <content stylecode="bold">without cirrhosis</content>
                                 </td>
                                 <td stylecode="Rrule Botrule" align="center">VIEKIRA PAK + ribavirin</td>
                                 <td stylecode="Botrule" align="center">12 weeks</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Botrule" align="center">
                                    <content stylecode="bold">Genotype 1a,</content>
                                    <br>
                                    <content stylecode="bold">with cirrhosis</content>
                                 </td>
                                 <td stylecode="Rrule Botrule" align="center">VIEKIRA PAK + ribavirin</td>
                                 <td stylecode="Botrule" align="center">24 weeks**</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Botrule" align="center">
                                    <content stylecode="bold">Genotype 1b, </content>
                                    <br>
                                    <content stylecode="bold">without cirrhosis</content>
                                 </td>
                                 <td stylecode="Rrule Botrule" align="center">VIEKIRA PAK </td>
                                 <td stylecode="Botrule" align="center">12 weeks</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Botrule" align="center">
                                    <content stylecode="bold">Genotype 1b, </content>
                                    <br>
                                    <content stylecode="bold">with cirrhosis</content>
                                 </td>
                                 <td stylecode="Rrule Botrule" align="center">VIEKIRA PAK + ribavirin</td>
                                 <td stylecode="Botrule" align="center">12 weeks</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule" colspan="3" align="left">*Note: Follow the genotype 1a dosing recommendations in patients with an unknown genotype 1 subtype or with mixed genotype 1 infection.<br>**VIEKIRA PAK administered with ribavirin for 12 weeks may be considered for some patients based on prior treatment history<content stylecode="italics"> [see Clinical Studies (<a href="#section_14.3">14.3</a>)]</content>.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_2_3" class="safetySubheading">2.3 Use in Liver Transplant Recipients</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p154612291393271755">In liver transplant recipients with normal hepatic function and mild fibrosis (Metavir fibrosis score 2 or lower), the recommended duration of VIEKIRA PAK with ribavirin is 24 weeks, irrespective of HCV genotype 1 subtype <content stylecode="italics"> [see Clinical Studies (<a href="#section_14.6">14.6</a>)]</content>. When VIEKIRA PAK is administered with calcineurin inhibitors in liver transplant recipients, dosage adjustment of calcineurin inhibitors is needed <content stylecode="italics">[see Drug Interactions (<a href="#section_7">7</a>)]</content>. </p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_2_4" class="safetySubheading">2.4 Hepatic Impairment</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p5197610291412791818">
                           <content stylecode="xmChange">VIEKIRA PAK is  contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh B and C)</content>
                           <content stylecode="italics">[see Contraindications (<a href="#section_4">4</a>), Warnings and Precautions (<a href="#section_5.1">5.1</a>), Use in Specific Populations (<a href="#section_8.6">8.6</a>), and Clinical Pharmacology (<a href="#section_12.3">12.3</a>)]</content>.</p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_43678-2">
<div class="drugSubheadings">
<span id="VIEKIRA_PAK_43678-2" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>3 DOSAGE FORMS AND STRENGTHS</div>
<div id="VIEKIRA_PAK_previewText_43678-2" class="previewText">
                  VIEKIRA PAK is ombitasvir, paritaprevir, ritonavir fixed dose
                        Tablets: 
                        
                    <span>...</span>
</div>
</div>
<div id="VIEKIRA_PAK_collapsableElement_43678-2" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText">
<text>
                  <p id="P7">VIEKIRA PAK is ombitasvir, paritaprevir, ritonavir fixed dose combination tablets copackaged with dasabuvir tablets.</p>
                  <ul ultype="unordered" id="l7983291393271986" stylecode="Disc">
                     <li>Ombitasvir, paritaprevir, ritonavir 12.5/75/50 mg tablets are pink-colored, film-coated, oblong biconvex shaped, debossed with “AV1” on one side.</li>
                     <li>Dasabuvir 250 mg tablets are beige-colored, film-coated, oval-shaped, debossed with “AV2” on one side. Each tablet contains 270.3 mg dasabuvir sodium monohydrate equivalent to 250 mg dasabuvir.</li>
                  </ul>
               </text><text>
                        <p id="p823212291392656188">Tablets: </p>
                        <ul ultype="unordered" id="l823510291392656196" stylecode="Disc">
                           <li>Ombitasvir, paritaprevir, ritonavir: 12.5/75/50 mg (<a href="#section_3">3</a>)</li>
                           <li>Dasabuvir: 250 mg (<a href="#section_3">3</a>)</li>
                        </ul>
                     </text>
</div></div>
</div>
<div class="section">
<div id="nonCollapsableElement_34070-3">
<div class="drugSubheadings">
<span id="VIEKIRA_PAK_34070-3" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>4 CONTRAINDICATIONS</div>
<div id="VIEKIRA_PAK_previewText_34070-3" class="previewText">
                  
                     
                        VIEKIRA PAK is
                        
                           If VIEKIRA PAK is administe<span>...</span>
</div>
</div>
<div id="VIEKIRA_PAK_collapsableElement_34070-3" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText">
<text>
                  <ul ultype="unordered" id="l509861291408746430" stylecode="Disc">
                     <li>
                        <content stylecode="xmChange">VIEKIRA PAK is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh B and C) due to risk of potential toxicity <content stylecode="italics">[see Warnings and Precautions (<a href="#section_5.1">5.1</a>), Use in Specific Populations (<a href="#section_8.6">8.6</a>) and Clinical Pharmacology (<a href="#section_12.3">12.3</a>)]</content>.</content>
                     </li>
                     <li>If VIEKIRA PAK is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. Refer to the ribavirin prescribing information for a ul of contraindications for ribavirin.</li>
                     <li>VIEKIRA PAK is contraindicated with:<ul ultype="unordered" id="l519814291413299387" stylecode="Circle">
                           <li>Drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events.</li>
                           <li>Drugs that are <content stylecode="xmChange">moderate or</content> strong inducers of CYP3A and <content stylecode="xmChange">strong inducers of</content> CYP2C8 and may lead to reduced efficacy of VIEKIRA PAK.</li>
                           <li>Drugs that are strong inhibitors of CYP2C8 and  may increase dasabuvir plasma concentrations and the risk of QT prolongation.</li>
                        </ul>
                     </li>
                  </ul>
                  <p id="p009">Table 2 uls drugs that are contraindicated with VIEKIRA PAK <content stylecode="italics">[see Drug Interactions (<a href="#section_7">7</a>)]</content>.</p>
                  <table id="table_2" cellpadding="6" frame="box" width="100%">
                     <caption>Table 2. Drugs that are Contraindicated with VIEKIRA PAK</caption>
                     <colgroup>
                        <col width="25%">
                        <col width="25%">
                        <col width="50%">
                     </colgroup>
                     <tbody>
                        <tr>
                           <td stylecode="Botrule Rrule" align="center">
                              <content stylecode="bold">Drug Class</content>
                           </td>
                           <td stylecode="Botrule Rrule" align="center">
                              <content stylecode="bold">Drug(s) within Class</content>
                              <br>
                              <content stylecode="bold">that are</content>
                              <br>
                              <content stylecode="bold">Contraindicated</content>
                           </td>
                           <td stylecode="Botrule" align="center">
                              <content stylecode="bold">Clinical Comments</content>
                           </td>
                        </tr>
                        <tr>
                           <td stylecode="Botrule Rrule" valign="top">Alpha1-adrenoreceptor<br>antagonist</td>
                           <td stylecode="Botrule Rrule" valign="top">Alfuzosin HCL</td>
                           <td stylecode="Botrule" valign="top">Potential for hypotension.</td>
                        </tr>
                        <tr>
                           <td stylecode="Botrule Rrule" valign="top">
                              <content stylecode="xmChange">Anti-gout</content>
                           </td>
                           <td stylecode="Botrule Rrule" valign="top">
                              <content stylecode="xmChange">Colchicine</content>
                           </td>
                           <td stylecode="Botrule" valign="top">
                              <content stylecode="xmChange">Potential for serious and/or life-threatening reactions in patients with renal and/or hepatic impairment.</content>
                           </td>
                        </tr>
                        <tr>
                           <td stylecode="Botrule Rrule" valign="top">Anticonvulsants</td>
                           <td stylecode="Botrule Rrule" valign="top">Carbamazepine,<br> phenytoin, <br>phenobarbital</td>
                           <td stylecode="Botrule" valign="top">Ombitasvir, paritaprevir, ritonavir and dasabuvir exposures may decrease leading to a potential loss of therapeutic activity of VIEKIRA PAK.</td>
                        </tr>
                        <tr>
                           <td stylecode="Botrule Rrule" valign="top">Antihyperlipidemic agent</td>
                           <td stylecode="Botrule Rrule" valign="top">Gemfibrozil</td>
                           <td stylecode="Botrule" valign="top">Increase in dasabuvir exposures by 10-fold which may increase the risk of QT prolongation.</td>
                        </tr>
                        <tr>
                           <td stylecode="Botrule Rrule" valign="top">Antimycobacterial</td>
                           <td stylecode="Botrule Rrule" valign="top">Rifampin</td>
                           <td stylecode="Botrule" valign="top">Ombitasvir, paritaprevir, ritonavir and dasabuvir exposures may decrease leading to a potential loss of therapeutic activity of VIEKIRA PAK.</td>
                        </tr>
                        <tr>
                           <td stylecode="Botrule Rrule" valign="top">Ergot derivatives</td>
                           <td stylecode="Botrule Rrule" valign="top">Ergotamine, dihydroergotamine, ergonovine, methylergonovine </td>
                           <td stylecode="Botrule" valign="top">Acute ergot toxicity characterized by vasospasm and tissue ischemia has been associated with co-administration of ritonavir and ergonovine, ergotamine, dihydroergotamine, or methylergonovine.</td>
                        </tr>
                        <tr>
                           <td stylecode="Botrule Rrule" valign="top">Ethinyl estradiol-containing products</td>
                           <td stylecode="Botrule Rrule" valign="top">Ethinyl estradiol-containing medications such as combined oral contraceptives</td>
                           <td stylecode="Botrule" valign="top">Potential for ALT elevations <content stylecode="italics">[see Warnings and Precautions (<a href="#section_5.2">5.2</a>)]</content>.</td>
                        </tr>
                        <tr>
                           <td stylecode="Botrule Rrule" valign="top">Herbal Product</td>
                           <td stylecode="Botrule Rrule" valign="top">St. John’s Wort <content stylecode="italics">(Hypericum perforatum)</content>
                           </td>
                           <td stylecode="Botrule" valign="top">Ombitasvir, paritaprevir, ritonavir and dasabuvir exposures may decrease leading to a potential loss of therapeutic activity of VIEKIRA PAK.</td>
                        </tr>
                        <tr>
                           <td stylecode="Botrule Rrule">HMG-CoA Reductase Inhibitors</td>
                           <td stylecode="Botrule Rrule" valign="top">Lovastatin, <br>simvastatin</td>
                           <td stylecode="Botrule" valign="top">Potential for myopathy including rhabdomyolysis.</td>
                        </tr>
                        <tr>
                           <td stylecode="Botrule Rrule" valign="top">Neuroleptics</td>
                           <td stylecode="Botrule Rrule" valign="top">Pimozide</td>
                           <td stylecode="Botrule" valign="top">Potential for cardiac arrhythmias.</td>
                        </tr>
                        <tr>
                           <td stylecode="Botrule Rrule" valign="top">Non-nucleoside reverse transcriptase inhibitor</td>
                           <td stylecode="Botrule Rrule" valign="top">Efavirenz</td>
                           <td stylecode="Botrule" valign="top">Co-administration of efavirenz based regimens with paritaprevir, ritonavir plus dasabuvir was poorly tolerated and resulted in liver enzyme elevations. </td>
                        </tr>
                        <tr>
                           <td stylecode="Botrule Rrule" valign="top">Phosphodiesterase-5 (PDE5) inhibitor</td>
                           <td stylecode="Botrule Rrule" valign="top">Sildenafil when dosed as REVATIO for the treatment of pulmonary arterial hypertension (PAH) </td>
                           <td stylecode="Botrule" valign="top">There is increased potential for sildenafil-associated adverse events such as visual disturbances, hypotension, priapism, and syncope.</td>
                        </tr>
                        <tr>
                           <td stylecode="Botrule Rrule" valign="top">Sedatives/hypnotics</td>
                           <td stylecode="Botrule Rrule" valign="top">Triazolam  <br>Orally administered midazolam</td>
                           <td stylecode="Botrule" valign="top">Triazolam and orally administered midazolam are extensively metabolized by CYP3A4. Coadministration of triazolam or orally administered midazolam with VIEKIRA PAK may cause large increases in the concentration of these benzodiazepines. The potential exists for serious and/or life threatening events such as prolonged or increased sedation or respiratory depression. </td>
                        </tr>
                     </tbody>
                  </table>
                  <ul ultype="unordered" id="l50969132381416535221" stylecode="Disc">
                     <li>VIEKIRA PAK is contraindicated in patients with known hypersensitivity (e.g. toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome) to ritonavir.</li>
                  </ul>
               </text><text>
                        <ul ultype="unordered" id="l113081291392656381" stylecode="Disc">
                           <li>If VIEKIRA PAK is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. (<a href="#section_4">4</a>)</li>
                           <li>Patients with moderate to severe hepatic impairment. (<a href="#section_4">4</a>, <a href="#section_5.1">5.1</a>, <a href="#section_8.6">8.6</a>, <a href="#section_12.3">12.3</a>)</li>
                           <li>Co-administration with drugs that are: highly dependent on CYP3A for clearance; moderate or strong inducers of CYP3A and strong inducers of CYP2C8; and strong inhibitors of CYP2C8. (<a href="#section_4">4</a>)</li>
                           <li>Known hypersensitivity to ritonavir (e.g. toxic epidermal necrolysis, Stevens-Johnson syndrome). (<a href="#section_4">4</a>)</li>
                        </ul>
                     </text>
</div></div>
</div>
<div class="section">
<div id="nonCollapsableElement_43685-7">
<div class="drugSubheadings">
<span id="VIEKIRA_PAK_43685-7" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>5 WARNINGS AND PRECAUTIONS</div>
<div id="VIEKIRA_PAK_previewText_43685-7" class="previewText">
                        
                           
                          <span>...</span>
</div>
</div>
<div id="VIEKIRA_PAK_collapsableElement_43685-7" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                        <ul ultype="unordered" id="l115593291392656521" stylecode="Disc">
                           <li>
                              <content stylecode="underline">Hepatic Decompensation and Hepatic Failure in Patient with Cirrhosis</content>: Hepatic decompensation and hepatic failure, including liver transplantation or fatal outcomes, have been reported mostly in patients with advanced cirrhosis. Monitor for clinical signs and symptoms of hepatic decompensation. (<a href="#section_5.1">5.1</a>)</li>
                           <li>
                              <content stylecode="underline">ALT Elevations</content>: Discontinue ethinyl estradiol-containing medications prior to starting VIEKIRA PAK (alternative contraceptive methods are recommended).  Perform hepatic laboratory testing on all patients during the first 4 weeks of treatment. For ALT elevations on VIEKIRA PAK, monitor closely and follow recommendations in full prescribing information. (<a href="#section_5.2">5.2</a>)</li>
                           <li>
                              <content stylecode="underline">Risks Associated With Ribavirin Combination Treatment</content>: If VIEKIRA PAK is administered with ribavirin, the warnings and precautions for ribavirin also apply to this combination regimen. (<a href="#section_5.3">5.3</a>)</li>
                           <li>
                              <content stylecode="underline">Drug Interactions</content>: The concomitant use of VIEKIRA PAK and certain other drugs may result in known or potentially significant drug interactions, some of which may lead to loss of therapeutic effect of VIEKIRA PAK. (<a href="#section_5.4">5.4</a>) </li>
                        </ul>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_5_1" class="safetySubheading">5.1 Risk of Hepatic Decompensation and Hepatic Failure in Patients with Cirrhosis</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p430576291444936998">
                           <content stylecode="xmChange">Hepatic decompensation and hepatic failure, including liver transplantation or fatal outcomes, have been reported postmarketing in patients treated with VIEKIRA PAK. Most patients with these severe outcomes had evidence of advanced cirrhosis prior to initiating therapy with VIEKIRA PAK. Reported cases typically occurred within one to four weeks of initiating therapy and were characterized by the acute onset of rising direct serum bilirubin levels without ALT elevations in association with clinical signs and symptoms of hepatic decompensation. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</content>
                        </p>
                        <p id="p532864291444937050">
                           <content stylecode="xmChange">VIEKIRA PAK is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh B and C) <content stylecode="italics">[see Contraindications (<a href="#section_4">4</a>), Adverse Reactions (<a href="#section_6.2">6.2</a>), Use in Specific Populations (<a href="#section_8.6">8.6</a>), and Clinical Pharmacology (<a href="#section_12.3">12.3</a>)]</content>.</content>
                        </p>
                        <p id="p535164291444937441">
                           <content stylecode="xmChange">For patients with cirrhosis</content>:</p>
                        <ul ultype="unordered" id="l535214291444937461" stylecode="Disc">
                           <li>
                              <content stylecode="xmChange">Monitor for clinical signs and symptoms of hepatic decompensation (such as ascites, hepatic encephalopathy, variceal hemorrhage).</content>
                           </li>
                           <li>
                              <content stylecode="xmChange">Hepatic laboratory testing including direct bilirubin levels should be performed at baseline and during the first 4 weeks of starting treatment and as clinically indicated.</content>
                           </li>
                           <li>
                              <content stylecode="xmChange">Discontinue VIEKIRA PAK in patients who develop evidence of hepatic decompensation.</content>
                           </li>
                        </ul>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_5_2" class="safetySubheading">5.2 Increased Risk of ALT Elevations</span><div id="43685-7" class="safetySubdescription"><text>
                        <p id="p361113291413300537">During clinical trials with VIEKIRA PAK with or without ribavirin, elevations of ALT to greater than 5 times the upper limit of normal (ULN) occurred in approximately 1% of all subjects <content stylecode="italics">[see Adverse Reactions (<a href="#section_6.1">6.1</a>)]</content>. ALT elevations were typically asymptomatic, occurred during the first 4 weeks of treatment, and declined within two to eight weeks of onset with continued dosing of VIEKIRA PAK with or without ribavirin.</p>
                        <p id="p38783291413300580">These ALT elevations were significantly more frequent in female subjects who were using ethinyl estradiol-containing medications such as combined oral contraceptives, contraceptive patches or contraceptive vaginal rings. Ethinyl estradiol-containing medications must be discontinued prior to starting therapy with VIEKIRA PAK <content stylecode="italics">[see Contraindications (<a href="#section_4">4</a>)]</content>. Alternative methods of contraception (e.g, progestin only contraception or non-hormonal methods) are recommended during VIEKIRA PAK therapy. Ethinyl estradiol-containing medications can be restarted approximately 2 weeks following completion of treatment with VIEKIRA PAK.</p>
                        <p id="p415005291415739169">Women using estrogens other than ethinyl estradiol, such as estradiol and conjugated estrogens used in hormone replacement therapy had a rate of ALT elevation similar to those not receiving any estrogens; however, due to the limited number of subjects taking these other estrogens, caution is warranted for co-administration with VIEKIRA PAK <content stylecode="italics">[see Adverse Reactions (<a href="#section_6.1">6.1</a>)]</content>.</p>
                        <p id="p496905291415739196">Hepatic laboratory testing should be performed during the first 4 weeks of starting treatment and as clinically indicated thereafter. If ALT is found to be elevated above baseline levels, it should be repeated and monitored closely:</p>
                        <ul ultype="unordered" id="l496971291415739222" stylecode="Disc">
                           <li>Patients should be instructed to consult their health care professional without delay if they have onset of fatigue, weakness, lack of appetite, nausea and vomiting, jaundice or discolored feces.</li>
                           <li>Consider discontinuing VIEKIRA PAK if ALT levels remain persistently greater than 10 times the ULN.</li>
                           <li>Discontinue VIEKIRA PAK if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing direct bilirubin, alkaline phosphatase, or INR.</li>
                        </ul>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_5_3" class="safetySubheading">5.3 Risks Associated With Ribavirin Combination Treatment</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p38574291413300700">If VIEKIRA PAK is administered with ribavirin, the warnings and precautions for ribavirin, in particular the pregnancy avoidance warning, apply to this combination regimen. Refer to the ribavirin prescribing information for a full ul of the warnings and precautions for ribavirin.</p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_5_4" class="safetySubheading">5.4 Risk of Adverse Reactions or Reduced Therapeutic Effect Due to Drug Interactions</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p4148592381416535590">The concomitant use of VIEKIRA PAK and certain other drugs may result in known or potentially significant drug interactions, some of which may lead to:</p>
                        <ul ultype="unordered" id="l5097792381416535599" stylecode="Disc">
                           <li>Loss of therapeutic effect of VIEKIRA PAK and possible development of resistance</li>
                           <li>Possible clinically significant adverse reactions from greater exposures of concomitant drugs or components of VIEKIRA PAK.</li>
                        </ul>
                        <p id="p4151392381416535621">See Table 5 for steps to prevent or manage these possible and known significant drug interactions, including dosing recommendations <content stylecode="italics">[see Drug Interactions (<a href="#section_7">7</a>)]</content>. Consider the potential for drug interactions prior to and during VIEKIRA PAK therapy; review concomitant medications during VIEKIRA PAK therapy; and monitor for the adverse reactions associated with the concomitant drugs <content stylecode="italics">[see Contraindications (<a href="#section_4">4</a>) and Drug Interactions (<a href="#section_7">7</a>)]</content>.</p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_5_5" class="safetySubheading">5.5 Risk of HIV-1 Protease Inhibitor Drug Resistance in HCV/HIV-1 Co-infected Patients</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p3886132381416535829">The ritonavir component of VIEKIRA PAK is also an HIV-1 protease inhibitor and can select for HIV-1 protease inhibitor resistance-associated substitutions.  Any HCV/HIV-1 co-infected patients treated with VIEKIRA PAK should also be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug resistance.</p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34084-4">
<div class="drugSubheadings">
<span id="VIEKIRA_PAK_34084-4" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>6 ADVERSE REACTIONS</div>
<div id="VIEKIRA_PAK_previewText_34084-4" class="previewText">
                  If VIEKIRA PAK is administered with ribavirin (RBV), refer to
                        In subjects receiving VIEKIRA PAK with ribavirin, the m<span>...</span>
</div>
</div>
<div id="VIEKIRA_PAK_collapsableElement_34084-4" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText">
<text>
                  <p id="p524823291412792984">If VIEKIRA PAK is administered with ribavirin (RBV), refer to the prescribing information for ribavirin for a ul of ribavirin-associated adverse reactions.</p>
                  <p id="p43635291413301132">The following adverse reaction is described below and elsewhere in the labeling:</p>
                  <ul ultype="unordered" id="l394701291413301140" stylecode="Disc">
                     <li>Risk of Hepatic Decompensation and Hepatic Failure in Patients with Cirrhosis <content stylecode="italics">[see Warnings and Precautions (<a href="#section_5.1">5.1</a>)]</content>
                     </li>
                     <li>Increased Risk of ALT Elevations <content stylecode="italics">[see Warnings and Precautions (<a href="#section_5.2">5.2</a>)]</content>
                     </li>
                  </ul>
               </text><text>
                        <p id="p122895291392657273">In subjects receiving VIEKIRA PAK with ribavirin, the most commonly reported adverse reactions (greater than 10% of subjects) were fatigue, nausea, pruritus, other skin reactions, insomnia and asthenia. In subjects receiving VIEKIRA PAK without ribavirin, the most commonly reported adverse reactions (greater than or equal to 5% of subjects) were nausea, pruritus and insomnia. (<a href="#section_6.1">6.1</a>)<br>
                           <br>
                        </p>
                        <p id="p123193291392657283">
                           <content stylecode="bold">To report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </p>
                     </text>
</div>
<span id="VIEKIRA_PAK_collapsableElement_6_1" class="safetySubheading">6.1 Clinical Trials Experience </span><div id="34084-4" class="safetySubdescription"><text>
                        <p id="p90055241370612716">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of VIEKIRA PAK cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
                        <p id="p952114291393274658">The safety assessment was based on data from six Phase 3 clinical trials in more than 2,000 subjects who received VIEKIRA PAK with or without ribavirin for 12 or 24 weeks.</p>
                        <p id="p43966291393274759">
                           <content stylecode="underline">VIEKIRA PAK with Ribavirin in Placebo-Controlled Trials</content>
                        </p>
                        <p id="p3255014291395751462">The safety of VIEKIRA PAK in combination with ribavirin was assessed in 770 subjects with chronic HCV infection in two placebo-controlled trials (SAPPHIRE-I and -II) <content stylecode="italics">[see Clinical Studies (<a href="#section_14.1">14.1</a>, <a href="#section_14.2">14.2</a>)]</content>. Adverse reactions that occurred more often in subjects treated with VIEKIRA PAK in combination with ribavirin compared to placebo were fatigue, nausea, pruritus, other skin reactions, insomnia, and asthenia (see <a href="#table_3">Table 3</a>). The majority of the adverse reactions were mild in severity. Two percent of subjects experienced a serious adverse event (SAE). The proportion of subjects who permanently discontinued treatment due to adverse reactions was less than 1%.</p>
                        <table id="table_3" frame="box" width="100%">
                           <caption>Table 3. Adverse Reactions with ≥5% Greater Frequency Reported in Subjects with Chronic HCV GT1 Infection Treated with VIEKIRA PAK in Combination with Ribavirin Compared to Placebo for 12 Weeks</caption>
                           <colgroup>
                              <col width="33*">
                              <col width="33*">
                              <col width="33*">
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule">&nbsp;</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" colspan="2" align="center">
                                    <content stylecode="bold">SAPPHIRE-I and -II</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule"></td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">
                                    <content stylecode="bold">VIEKIRA PAK + RBV</content>
                                    <br>
                                    <content stylecode="bold">12 Weeks</content>
                                    <br>
                                    <content stylecode="bold">N = 770</content>
                                    <br>
                                    <content stylecode="bold">%</content>
                                 </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center" valign="top">
                                    <content stylecode="bold">Placebo</content>
                                    <br>
                                    <content stylecode="bold">12 Weeks</content>
                                    <br>
                                    <content stylecode="bold">N = 255</content>
                                    <br>
                                    <content stylecode="bold">%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">Fatigue</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">34 </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">26</td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">Nausea</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">22 </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">15 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">Pruritus*</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">18 </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">7 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">Skin reactions<sup>$</sup>
                                 </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">16</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">9</td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">Insomnia</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">14</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">8 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">Asthenia</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">14 </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">7</td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" colspan="3">*Grouped term ‘pruritus’ included the preferred terms pruritus and pruritus generalized.<br>
                                    <sup>$</sup>Grouped terms: rash, erythema, eczema, rash maculo-papular, rash macular, dermatitis, rash papular, skin exfoliation, rash pruritic, rash erythematous, rash generalized, dermatitis allergic, dermatitis contact, exfoliative rash, photosensitivity reaction, psoriasis, skin reaction, ulcer, urticaria.</td>
                              </tr>
                           </tbody>
                        </table>
                        <p id="p529954291412795959">
                           <content stylecode="underline">VIEKIRA PAK with and without Ribavirin in Regimen-Controlled Trials</content>
                        </p>
                        <p id="p530134291412798870">VIEKIRA PAK with and without ribavirin was assessed in 401 and 509 subjects with chronic HCV infection, respectively, in three clinical trials (PEARL-II, PEARL-III and PEARL-IV) <content stylecode="italics">[see Clinical Studies (<a href="#section_14.1">14.1</a>, <a href="#section_14.2">14.2</a>)]</content>. Pruritus, nausea, insomnia, and asthenia were identified as adverse events occurring more often in subjects treated with VIEKIRA PAK in combination with ribavirin (see <a href="#table_4">Table 4</a>). The majority of adverse events were mild to moderate in severity. The proportion of subjects who permanently discontinued treatment due to adverse events was less than 1% for both VIEKIRA PAK in combination with ribavirin and VIEKIRA PAK alone.</p>
                        <table id="table_4" frame="box" width="100%">
                           <caption>Table 4. Adverse Events with ≥5% Greater Frequency Reported in Subjects with Chronic HCV GT1 Infection Treated with VIEKIRA PAK in Combination with Ribavirin Compared to VIEKIRA PAK for 12 Weeks</caption>
                           <colgroup>
                              <col width="33*">
                              <col width="33*">
                              <col width="33*">
                           </colgroup>
                           <thead>
                              <tr>
                                 <th stylecode="Toprule Botrule Lrule Rrule">&nbsp;</th>
                                 <th stylecode="Toprule Botrule Lrule Rrule" colspan="2" align="center">
                                    <content stylecode="bold">PEARL-II, -III and -IV</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule"></td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">
                                    <content stylecode="bold">VIEKIRA PAK + RBV</content>
                                    <br>
                                    <content stylecode="bold">12 Weeks</content>
                                    <br>
                                    <content stylecode="bold">N = 401</content>
                                    <br>
                                    <content stylecode="bold">%</content>
                                 </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center" valign="top">
                                    <content stylecode="bold">VIEKIRA PAK</content>
                                    <br>
                                    <content stylecode="bold">12 Weeks</content>
                                    <br>
                                    <content stylecode="bold">N = 509</content>
                                    <br>
                                    <content stylecode="bold">%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">Nausea</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">16 </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">8 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">Pruritus*</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">13 </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">7 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">Insomnia</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">12</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">5 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">Asthenia</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">9 </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">4</td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" colspan="3">*Grouped term ‘pruritus’ included the preferred terms pruritus and pruritus generalized.</td>
                              </tr>
                           </tbody>
                        </table>
                        <p id="p530193291412796365">
                           <content stylecode="underline">VIEKIRA PAK with Ribavirin in Subjects with Compensated Cirrhosis </content>
                        </p>
                        <p id="p530184291412796382">VIEKIRA PAK with ribavirin was assessed in 380 subjects with compensated cirrhosis who were treated for 12 (n=208) or 24 (n=172) weeks duration (TURQUOISE-II) <content stylecode="italics">[see Clinical Studies (<a href="#section_14.1">14.1</a>, <a href="#section_14.3">14.3</a>)]</content>. The type and severity of adverse events in subjects with compensated cirrhosis was comparable to non-cirrhotic subjects in other phase 3 trials. Fatigue, skin reactions and dyspnea occurred at least 5% more often in subjects treated for 24 weeks. The majority of adverse events occurred during the first 12 weeks of dosing in both treatment arms. Most of the adverse events were mild to moderate in severity. The proportion of subjects treated with VIEKIRA PAK for 12 and 24 weeks with SAEs was 6% and 5%, respectively and 2% of subjects permanently discontinued treatment due to adverse events in each treatment arm.</p>
                        <p id="p46107291412796443">
                           <content stylecode="underline">Skin Reactions</content>
                        </p>
                        <p id="p61744291412796478">	In PEARL-II, -III and -IV, 7% of subjects receiving VIEKIRA PAK alone and 10% of subjects  receiving VIEKIRA PAK with ribavirin reported rash-related events.  In SAPPHIRE-I and -II 16% of subjects receiving VIEKIRA PAK with ribavirin and 9% of subjects receiving placebo reported skin reactions. In TURQUOISE-II, 18% and 24% of subjects receiving VIEKIRA PAK with ribavirin for 12 or 24 weeks reported skin reactions. The majority of events were graded as mild in severity. There were no serious events or severe cutaneous reactions, such as Stevens Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), erythema multiforme (EM) or drug rash with eosinophilia and systemic symptoms (DRESS).</p>
                        <p id="p61793291412796568">
                           <content stylecode="underline">Laboratory Abnormalities</content>
                        </p>
                        <p id="p519823291428506780">
                           <content stylecode="italics">Serum ALT Elevations</content>
                        </p>
                        <p id="p427674291428506828">Approximately 1% of subjects treated with VIEKIRA PAK experienced post-baseline serum ALT levels greater than 5 times the upper limit of normal (ULN) after starting treatment.&nbsp;The incidence increased to 25% (4/16) among women taking a concomitant ethinyl estradiol containing medication <content stylecode="italics">[see Contraindications (<a href="#section_4">4</a>) and Warnings and Precautions (<a href="#section_5.2">5.2</a>)]</content>. The incidence of clinically relevant ALT elevations among women using estrogens other than ethinyl estradiol, such as estradiol and conjugated estrogens used in hormone replacement therapy was 3% (2/59).</p>
                        <p id="p519863291428506872">ALT elevations were typically asymptomatic, generally occurred during the first 4 weeks of treatment (mean time 20 days, range 8-57 days) and most resolved with ongoing therapy. The majority of these ALT elevations were assessed as drug-related liver injury. Elevations in ALT were generally not associated with bilirubin elevations. Cirrhosis was not a risk factor for elevated ALT <content stylecode="italics">[see Warnings and Precautions (<a href="#section_5.2">5.2</a>)]</content>.</p>
                        <p id="p507095291413575457">
                           <content stylecode="italics">Serum Bilirubin Elevations</content>
                        </p>
                        <p id="p425367291413575476">Post-baseline elevations in bilirubin at least 2 x ULN were observed in 15% of subjects receiving VIEKIRA PAK with ribavirin compared to 2% in those receiving VIEKIRA PAK alone. These bilirubin increases were predominately indirect and related to the inhibition of the bilirubin transporters OATP1B1/1B3 by paritaprevir and ribavirin-induced hemolysis. Bilirubin elevations occurred after initiation of treatment, peaked by study Week 1, and generally resolved with ongoing therapy. Bilirubin elevations were not associated with serum ALT elevations.</p>
                        <p id="p56513291413575493">
                           <content stylecode="italics">Anemia/Decreased Hemoglobin</content>
                        </p>
                        <p id="p420184291417711475">Across all Phase 3 studies, the mean change from baseline in hemoglobin levels in subjects treated with VIEKIRA PAK in combination with ribavirin was -2.4 g/dL and the mean change in subjects treated with VIEKIRA PAK alone was -0.5 g/dL. Decreases in hemoglobin levels occurred early in treatment (Week 1-2) with further reductions through Week 3. Hemoglobin values remained low during the remainder of treatment and returned towards baseline levels by post-treatment Week 4. Less than 1% of subjects treated with VIEKIRA PAK with ribavirin had hemoglobin levels decrease to less than 8.0 g/dL during treatment.  Seven percent of subjects treated with VIEKIRA PAK in combination with ribavirin underwent a ribavirin dose reduction due to a decrease in hemoglobin levels; three subjects received a blood transfusion and five required erythropoietin.  One patient discontinued therapy due to anemia. No subjects treated with VIEKIRA PAK alone had a hemoglobin level less than 10 g/dL.</p>
                        <p id="p76993291412797927">
                           <content stylecode="underline">VIEKIRA PAK in HCV/HIV-1 Co-infected Subjects</content>
                        </p>
                        <p id="p76984291412797941">VIEKIRA PAK with ribavirin was assessed in 63 subjects with HCV/HIV-1 co-infection who were on stable antiretroviral therapy. The most common adverse events occurring in at least 10% of subjects were fatigue (48%), insomnia (19%), nausea (17%), headache (16%), pruritus (13%), cough (11%), irritability (10%), and ocular icterus (10%).</p>
                        <p id="p76944291412797949">Elevations in total bilirubin greater than 2 x&nbsp;ULN (mostly indirect) occurred in 34 (54%) subjects.  Fifteen of these subjects were also receiving atazanavir at the time of bilirubin elevation and nine also had adverse events of ocular icterus, jaundice or hyperbilirubinemia. None of the subjects with hyperbilirubinemia had concomitant elevations of aminotransferases <content stylecode="italics">[see Warnings and Precautions (<a href="#section_5.5">5.5</a>), Adverse Reactions (<a href="#section_6.1">6.1</a>) and Clinical Studies (<a href="#section_14.6">14.6</a>)]</content>. No subject experienced a grade 3 ALT elevation.</p>
                        <p id="p56624291415740729">Seven subjects (11%) had at least one post-baseline hemoglobin value of less than 10 g/dL, and six of these subjects had a ribavirin dose modification; no subject in this small cohort required a blood transfusion or erythropoietin.</p>
                        <p id="p56604291415740735">Median declines in CD4+ T-cell counts of 47 cells/mm<sup>3</sup> and 62 cells/mm<sup>3</sup> were observed at the end of 12 and 24 weeks of treatment, respectively, and most returned to baseline levels post-treatment. Two subjects had CD4+ T-cell counts decrease to less than 200 cells/mm<sup>3</sup> during treatment without a decrease in CD4%. No subject experienced an AIDS-related opportunistic infection.</p>
                        <p id="p76813291412798009">
                           <content stylecode="underline">VIEKIRA PAK in Selected Liver Transplant Recipients</content>
                        </p>
                        <p id="p64494291412798021">VIEKIRA PAK with ribavirin was assessed in 34 post-liver transplant subjects with recurrent HCV infection. Adverse events occurring in more than 20% of subjects included fatigue 50%, headache 44%, cough 32%, diarrhea 26%, insomnia 26%, asthenia 24%, nausea 24%, muscle spasms 21% and rash 21%.  Ten subjects (29%) had at least one post-baseline hemoglobin value of less than 10 g/dL. Ten subjects underwent a ribavirin dose modification due to decrease in hemoglobin and 3% (1/34) had an interruption of ribavirin. Five subjects received erythropoietin, all of whom initiated ribavirin at the starting dose of 1000 to 1200 mg daily. No subject received a blood transfusion <content stylecode="italics">[see Clinical Studies (<a href="#section_14.5">14.5</a>)]</content>.</p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_6_2" class="safetySubheading">6.2 Post-Marketing Adverse Reactions</span><div id="34084-4" class="safetySubdescription"><text>
                        <p id="p535213291444938271">The following adverse reactions have been identified during post approval use of VIEKIRA PAK. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
                        <p id="p425177291428496363">
                           <content stylecode="underline">Immune System Disorders:</content> Hypersensitivity reactions (including angioedema).</p>
                        <p id="p532511291444920311">
                           <content stylecode="underline">Hepatobiliary Disorders:</content> Hepatic decompensation, hepatic failure <content stylecode="italics">[see Warnings and Precautions (<a href="#section_5.1">5.1</a>)]</content>.</p>
                     </text></div>
</div>
</div>
<div class="section riskhide">
<div id="nonCollapsableElement_34073-7">
<div class="drugSubheadings">
<span id="VIEKIRA_PAK_34073-7" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>7 DRUG INTERACTIONS</div>
<div id="VIEKIRA_PAK_previewText_34073-7" class="previewText">
                  
                     See also Contraindications (4), Warning
                        Co-administration of VIEKIRA PAK can alter the plasma c<span>...</span>
</div>
</div>
<div id="VIEKIRA_PAK_collapsableElement_34073-7" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText">
<text>
                  <p id="p133325291393359498">
                     <content stylecode="italics">See also Contraindications (<a href="#section_4">4</a>), Warnings and Precautions (<a href="#section_5.4">5.4</a>), and Clinical Pharmacology (<a href="#section_12.3">12.3</a>).</content>
                  </p>
               </text><text>
                        <p id="p105432291392656968">Co-administration of VIEKIRA PAK can alter the plasma concentrations of some drugs and some drugs may alter the plasma concentrations of VIEKIRA PAK. The potential for drug interactions must be considered before and during treatment. Consult the full prescribing information prior to and during treatment for potential drug interactions. (<a href="#section_4">4</a>, <a href="#section_5.4">5.4</a>, <a href="#section_7">7</a>, <a href="#section_12.3">12.3</a>)</p>
                     </text>
</div>
<span id="VIEKIRA_PAK_collapsableElement_7_1" class="safetySubheading">7.1 Potential for VIEKIRA PAK to Affect Other Drugs </span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p97608291393359740">Ombitasvir, paritaprevir, and dasabuvir are inhibitors of UGT1A1, and ritonavir is an inhibitor of CYP3A4. Paritaprevir is an inhibitor of OATP1B1 and OATP1B3 and paritaprevir, ritonavir and dasabuvir are inhibitors of BCRP. Co-administration of VIEKIRA PAK with drugs that are substrates of CYP3A, UGT1A1, BCRP, OATP1B1 or OATP1B3 may result in increased plasma concentrations of such drugs. </p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_7_2" class="safetySubheading">7.2 Potential for Other Drugs to Affect One or More Components of VIEKIRA PAK</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p947414291393359886">Paritaprevir and ritonavir are primarily metabolized by CYP3A enzymes. Co-administration of VIEKIRA PAK with strong inhibitors of CYP3A may increase paritaprevir and ritonavir concentrations. Dasabuvir is primarily metabolized by CYP2C8 enzymes. Co-administration of VIEKIRA PAK with drugs that inhibit CYP2C8 may increase dasabuvir plasma concentrations. Ombitasvir is primarily metabolized via amide hydrolysis while CYP enzymes play a minor role in its metabolism. Ombitasvir, paritaprevir, dasabuvir and ritonavir are substrates of P-gp. Ombitasvir, paritaprevir and dasabuvir are substrates of BCRP. Paritaprevir is a substrate of OATP1B1 and OATP1B3. Inhibition of P-gp, BCRP, OATP1B1 or OATP1B3 may increase the plasma concentrations of the various components of VIEKIRA PAK.</p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_" class="safetySubheading">
                        7.3 Established and Other Potential Drug Interactions 
                     </span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p138401291393360042">If dose adjustments of concomitant medications are made due to treatment with VIEKIRA PAK, doses should be re-adjusted after administration of VIEKIRA PAK is completed. Dose adjustment is not required for VIEKIRA PAK.</p>
                        <p id="p66753291395762943">
                           <a href="#table_5">Table 5</a> provides the effect of co-administration of VIEKIRA PAK on concentrations of concomitant drugs  and the effect of concomitant drugs on the various components of VIEKIRA PAK. See <content stylecode="italics">Contraindications (<a href="#section_4">4</a>)</content> for drugs that are contraindicated with VIEKIRA PAK. Refer to the ritonavir prescribing information for other potentially significant drug interactions with ritonavir.</p>
                        <table id="table_5" frame="box" width="100%">
                           <caption>Table 5. Established Drug Interactions Based on Drug Interaction Trials</caption>
                           <colgroup>
                              <col width="24%">
                              <col width="25%">
                              <col width="49%">
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">
                                    <content stylecode="bold">Concomitant Drug Class: Drug Name</content>
                                 </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">
                                    <content stylecode="bold">Effect on Concentration</content>
                                 </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="center">
                                    <content stylecode="bold">Clinical Comments</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" colspan="3" align="left" valign="top">
                                    <content stylecode="bold">ANTIPSYCHOTIC</content>
                                 </td>
                              </tr>
                              <tr valign="top">
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="left">quetiapine<sup>*</sup>
                                 </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="left">↑ quetiapine</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" align="left">
                                    <ul ultype="unordered" id="l77241291432297064" stylecode="Disc">
                                       <li>Initiation of VIEKIRA PAK in patients taking quetiapine: Consider alternative anti-HCV therapy to avoid increases in quetiapine exposures. If coadministration is necessary, reduce the quetiapine dose to 1/6<sup>th</sup> of the current dose and monitor for quetiapine-associated adverse reactions.&nbsp;Refer to the quetiapine prescribing information for the recommendations on adverse reaction monitoring.</li>
                                       <li>Initiation of quetiapine in patients taking VIEKIRA PAK: Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine.</li>
                                    </ul>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" colspan="3">
                                    <content stylecode="bold">ANTIARRHYTHMICS</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule">amiodarone<sup>*</sup>,<br>bepridil<sup>*</sup>,<br>disopyramide<sup>*</sup>,<br>flecainide<sup>*</sup>,<br>lidocaine (systemic)<sup>*</sup>,<br>mexiletine<sup>*</sup>,<br>propafenone<sup>*</sup>,<br>quinidine<sup>*</sup>
                                 </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">↑ antiarrhythmics</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">Caution is warranted and therapeutic concentration monitoring (if available) is recommended for antiarrhythmics when co-administered with VIEKIRA PAK. </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" colspan="3">
                                    <content stylecode="bold">ANTIFUNGALS</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">ketoconazole</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">↑ ketoconazole</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule">When VIEKIRA PAK is co-administered with ketoconazole, the maximum daily dose of ketoconazole should be limited to 200 mg per day.</td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">voriconazole<sup>*</sup>
                                 </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">↓ voriconazole </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule">Co-administration of VIEKIRA PAK with voriconazole is not recommended unless an assessment of the benefit-to-risk ratio justifies the use of voriconazole.</td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" colspan="3" valign="top">
                                    <content stylecode="bold">CALCIUM CHANNEL BLOCKERS</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">amlodipine</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">↑ amlodipine</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule">Consider dose reduction for amlodipine.  Clinical monitoring is recommended.</td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" colspan="3">
                                    <content stylecode="bold">CORTICOSTEROIDS (INHALED/NASAL)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">fluticasone<sup>*</sup>
                                 </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">↑ fluticasone</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule">Concomitant use of VIEKIRA PAK with inhaled or nasal fluticasone may reduce serum cortisol concentrations.  Alternative corticosteroids should be considered, particularly for long term use.  </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" colspan="3">
                                    <content stylecode="bold">DIURETICS</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">furosemide</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">↑ furosemide (C<sub>max</sub>)</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule">Clinical monitoring of patients is recommended and therapy should be individualized based on patient’s response.</td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" colspan="3">
                                    <content stylecode="bold">HIV-ANTIVIRAL AGENTS</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">atazanavir/ritonavir once daily </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">↑ paritaprevir</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">When coadministered with VIEKIRA PAK, atazanavir 300 mg (without ritonavir) should only be given in the morning.</td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">darunavir/ritonavir</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">↓ darunavir (C<sub>trough</sub>)</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">Co-administration of VIEKIRA PAK with darunavir/ritonavir  is not recommended.</td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">lopinavir/ritonavir</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">↑ paritaprevir</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">Co-administration of VIEKIRA PAK with lopinavir/ritonavir is not recommended.</td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">rilpivirine </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">↑ rilpivirine</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">Co-administration of VIEKIRA PAK with rilpivirine once daily is not recommended due to potential for QT interval prolongation with higher concentrations of rilpivirine.</td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" colspan="3">
                                    <content stylecode="bold">HMG CoA REDUCTASE INHIBITORS</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">rosuvastatin</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">↑ rosuvastatin</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule">When VIEKIRA PAK is co-administered with rosuvastatin, the dose of rosuvastatin should not exceed 10 mg per day.</td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">pravastatin</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">↑ pravastatin</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule">When VIEKIRA PAK is co-administered with pravastatin, the dose of pravastatin should not exceed 40 mg per day.</td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" colspan="3">
                                    <content stylecode="bold">IMMUNOSUPPRESSANTS</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">cyclosporine</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">↑ cyclosporine</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule">When initiating therapy with VIEKIRA PAK, reduce cyclosporine dose to 1/5<sup>th</sup> of the patient’s current cyclosporine dose. Measure cyclosporine blood concentrations to determine subsequent dose modifications.  Upon completion of VIEKIRA PAK therapy, the appropriate time to resume pre-VIEKIRA PAK dose of cyclosporine should be guided by assessment of cyclosporine blood concentrations. Frequent assessment of renal function and cyclosporine-related side effects is recommended. </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">tacrolimus</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">↑ tacrolimus</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule">When initiating therapy with VIEKIRA PAK, the dose of tacrolimus needs to be reduced.  Do not administer tacrolimus on the day VIEKIRA PAK is initiated. Beginning the day after VIEKIRA PAK is initiated; reinitiate tacrolimus at a reduced dose based on tacrolimus blood concentrations.  Typical tacrolimus dosing is 0.5 mg every 7 days.<br> Measure tacrolimus blood concentrations and adjust dose or dosing frequency to determine subsequent dose modifications.  Upon completion of VIEKIRA PAK therapy, the appropriate time to resume pre-VIEKIRA PAK dose of tacrolimus should be guided by assessment of tacrolimus blood concentrations. Frequent assessment of renal function and tacrolimus related side effects is recommended. </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" colspan="3">
                                    <content stylecode="bold">LONG ACTING BETA-ADRENOCEPTOR AGONIST</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">salmeterol<sup>*</sup>
                                 </td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">↑ salmeterol</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule">Concurrent administration of VIEKIRA PAK and salmeterol is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.</td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" colspan="3">
                                    <content stylecode="bold">NARCOTIC ANALGESICS</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">buprenorphine/naloxone</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">↑ buprenorphine<br>↑ norbuprenorphine</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">No dose adjustment of buprenorphine/naloxone is required upon co-administration with VIEKIRA PAK.  Patients should be closely monitored for sedation and cognitive effects.</td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" colspan="3">
                                    <content stylecode="bold">PROTON PUMP INHIBITORS</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">omeprazole</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">↓ omeprazole</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule">Monitor patients for decreased efficacy of omeprazole.&nbsp;Consider increasing the omeprazole dose in patients whose symptoms are not well controlled; avoid use of more than 40 mg per day of omeprazole.</td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" colspan="3">
                                    <content stylecode="bold">SEDATIVES/HYPNOTICS</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">alprazolam</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule" valign="top">↑ alprazolam</td>
                                 <td stylecode="Toprule Botrule Lrule Rrule">Clinical monitoring of patients is recommended. A decrease in alprazolam dose can be considered based on clinical response.</td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule Lrule Rrule" colspan="3" valign="top">
                                    <content stylecode="italics">See Clinical Pharmacology, Tables <a href="#table_6">6</a> and <a href="#table_7">7</a>
                                    </content>.<br>The direction of the arrow indicates the direction of the change in exposures (C<sub>max</sub> and AUC) (↑ =<content stylecode="italics"> increase of more than 20%,</content> ↓ = <content stylecode="italics">decrease of more than 20%,</content> ↔ = <content stylecode="italics">no change or change less than 20%).</content>
                                    <br>
                                    <sup>*</sup>not studied.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_7_4" class="safetySubheading">7.4 Drugs without Clinically Significant Interactions with VIEKIRA PAK</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p130988291393947814">No dose adjustments are recommended when VIEKIRA PAK is co-administered with the following medications: digoxin, duloxetine, emtricitabine/tenofovir disoproxil fumarate,  escitalopram,  methadone, progestin only contraceptives, raltegravir, warfarin and zolpidem.</p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_43684-0">
<div class="drugSubheadings">
<span id="VIEKIRA_PAK_43684-0" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>8 USE IN SPECIFIC POPULATIONS</div>
<div id="VIEKIRA_PAK_previewText_43684-0" class="previewText"><span>...</span></div>
</div>
<div id="VIEKIRA_PAK_collapsableElement_43684-0" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"></div>
<span id="VIEKIRA_PAK_collapsableElement_8_1" class="safetySubheading">8.1 Pregnancy</span><div id="42228-7" class="safetySubdescription"><text>
                        <p id="p871415291393947985">Pregnancy Category B</p>
                        <p id="p4303342321417656300">
                           <content stylecode="underline">Pregnancy Exposure Registry</content>
                        </p>
                        <p id="p4150242321417656343">There is an Antiretroviral Pregnancy Registry that monitors pregnancy outcomes in women who are HCV/HIV-1 co-infected and taking concomitant antiretrovirals. Physicians are encouraged to register patients by calling 1-800-258-4263.</p>
                        <p id="p397175291412961664">
                           <content stylecode="underline">Risk Summary</content>
                        </p>
                        <p id="p151384291393948039">Adequate and well controlled studies with VIEKIRA PAK have not been conducted in pregnant women. In animal reproduction studies, no evidence of teratogenicity was observed with the administration of ombitasvir (mice and rabbits), paritaprevir, ritonavir (mice and rats), or dasabuvir (rats and rabbits) at exposures higher than the recommended clinical dose [see Data]. Because animal reproduction studies are not always predictive of human response, VIEKIRA PAK should be used during pregnancy only if clearly needed. </p>
                        <p id="p90084291412961736">If VIEKIRA PAK is administered with ribavirin, the combination regimen is contraindicated in pregnant women and in men whose female partners are pregnant. Refer to the ribavirin prescribing information for more information on use in pregnancy.</p>
                        <p id="p90024291412961788">
                           <content stylecode="underline">Data</content>
                        </p>
                        <p id="p56733291413575672">
                           <content stylecode="italics">Animal data</content>
                        </p>
                        <p id="p430087291413575691">In animal reproduction studies, there was no evidence of teratogenicity in offspring born to animals treated throughout pregnancy with ombitasvir and its major inactive human metabolites (M29, M36), paritaprevir, ritonavir, or dasabuvir. For ombitasvir, the highest dose tested produced exposures approximately 28-fold (mouse) or 4-fold (rabbit) the exposures in humans at the recommended clinical dose. The highest doses of the major, inactive human metabolites similarly tested produced exposures approximately 26-fold the exposures in humans at the recommended clinical dose. For paritaprevir, ritonavir, the highest doses tested produced exposures approximately 98-fold (mouse) or 8-fold (rat) the exposures in humans at the recommended clinical dose. For dasabuvir, the highest dose tested produced exposures approximately 24-fold (rat) or 6-fold (rabbit) the exposures in humans at the recommended clinical dose.</p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_8_3" class="safetySubheading">8.3 Nursing Mothers</span><div id="34080-2" class="safetySubdescription"><text>
                        <p id="p404774291412975453">It is not known whether any of the components of VIEKIRA PAK or their metabolites are present in human milk. Unchanged ombitasvir, paritaprevir and its hydrolysis product M13, and dasabuvir were the predominant components observed in the milk of lactating rats, without effect on nursing pups. </p>
                        <p id="p404726291412975462">The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VIEKIRA PAK and any potential adverse effects on the breastfed child from VIEKIRA PAK or from the underlying maternal condition.</p>
                        <p id="p404824291412975478">If VIEKIRA PAK is administered with ribavirin, the nursing mothers information for ribavirin also applies to this combination regimen (see prescribing information for ribavirin).</p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_8_4" class="safetySubheading">8.4 Pediatric Use</span><div id="34081-0" class="safetySubdescription"><text>
                        <p id="P18">Safety and effectiveness of VIEKIRA PAK in pediatric patients less than 18 years of age have not been established.</p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_8_5" class="safetySubheading">8.5 Geriatric Use</span><div id="34082-8" class="safetySubdescription"><text>
                        <p id="P19">No dosage adjustment of VIEKIRA PAK is warranted in geriatric patients. Of the total number of subjects in clinical studies of VIEKIRA PAK, 8.5% (174/2053) were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.</p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_8_6" class="safetySubheading">8.6 Hepatic Impairment</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p512223291416542855">No dosage adjustment of VIEKIRA PAK is required in patients with mild hepatic impairment (Child-Pugh A). VIEKIRA PAK is contraindicated in patients with moderate to severe (Child-Pugh B and C) hepatic impairment <content stylecode="italics">[see Contraindications (<a href="#section_4">4</a>), Warnings and Precautions (<a href="#section_5.1">5.1</a>) and Clinical Pharmacology (<a href="#section_12.3">12.3</a>)]</content>.</p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_8_7" class="safetySubheading">8.7 Renal Impairment</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p1333611291393948697">No dosage adjustment of VIEKIRA PAK is required in patients with mild, moderate or severe renal impairment. VIEKIRA PAK has not been studied in patients on dialysis. For patients that require ribavirin, refer to the ribavirin prescribing information for information regarding use in patients with renal impairment <content stylecode="italics">[see Clinical Pharmacology (<a href="#section_12.3">12.3</a>)]</content>.</p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_8_8" class="safetySubheading">8.8 Other HCV Genotypes</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p135948291393948895">The safety and efficacy of VIEKIRA PAK has not been established in patients with HCV genotypes other than genotype 1.</p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34088-5">
<div class="drugSubheadings">
<span id="VIEKIRA_PAK_34088-5" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>10 OVERDOSAGE</div>
<div id="VIEKIRA_PAK_previewText_34088-5" class="previewText">
                  In case of overdose, it is recommended that the patient be mo<span>...</span>
</div>
</div>
<div id="VIEKIRA_PAK_collapsableElement_34088-5" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"><text>
                  <p id="P24">In case of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment instituted immediately.</p>
               </text></div></div>
</div>
<div class="section">
<div id="nonCollapsableElement_34089-3">
<div class="drugSubheadings">
<span id="VIEKIRA_PAK_34089-3" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>11 DESCRIPTION</div>
<div id="VIEKIRA_PAK_previewText_34089-3" class="previewText">
                  VIEKIRA PAK is ombitasvir, paritaprevir, ritonavir fixed dose<span>...</span>
</div>
</div>
<div id="VIEKIRA_PAK_collapsableElement_34089-3" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                  <p id="p261186241373652946">VIEKIRA PAK is ombitasvir, paritaprevir, ritonavir fixed dose combination tablets copackaged with dasabuvir tablets.</p>
                  <p id="p156538291393949195">Ombitasvir, paritaprevir, ritonavir fixed dose combination tablet includes a hepatitis C virus NS5A inhibitor (ombitasvir), a hepatitis C virus NS3/4A protease inhibitor (paritaprevir), and a CYP3A inhibitor (ritonavir) that inhibits CYP3A mediated metabolism of paritaprevir, thereby providing increased plasma concentration of paritaprevir. Dasabuvir is a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor, which is supplied as separate tablets in the copackage. Both tablets are for oral administration.</p>
                  <p id="p102664291393949674">
                     <content stylecode="underline">Ombitasvir</content>
                  </p>
                  <p id="p102414291393949703">The chemical name of ombitasvir is Dimethyl ([(2<content stylecode="italics">S</content>,5<content stylecode="italics">S</content>)-1-(4-<content stylecode="italics">tert</content>-butylphenyl) pyrrolidine-2,5-diyl]bis{benzene-4,1-diylcarbamoyl(2<content stylecode="italics">S</content>)pyrrolidine-2,1-diyl[(2<content stylecode="italics">S</content>)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate hydrate. The molecular formula is C<sub>50</sub>H<sub>67</sub>N<sub>7</sub>O<sub>8</sub>•4.5H<sub>2</sub>O (hydrate) and the molecular weight for the drug substance is 975.20 (hydrate).&nbsp; The drug substance is white to light yellow to light pink powder, and is practically insoluble in aqueous buffers but is soluble in ethanol. Ombitasvir has the following molecular structure:</p>
                  <rendermultimedia referencedobject="g107853291418933793"></rendermultimedia>
                  <p id="p1358113291393949275">
                     <content stylecode="underline">Paritaprevir</content>
                  </p>
                  <p id="p135840291393949290">The chemical name of paritaprevir is (2R,6S,12Z,13aS,14aR,16aS)-N-(cyclopropylsulfonyl)-6-{[(5-methylpyrazin-2-yl)carbonyl]amino}-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[<content stylecode="italics">e</content>]pyrrolo[1,2-<content stylecode="italics">a</content>][1,4] diazacyclopentadecine-14a(5H)-carboxamide dihydrate. The molecular formula is C<sub>40</sub>H<sub>43</sub>N<sub>7</sub>O<sub>7</sub>S•2H<sub>2</sub>O (dihydrate) and the molecular weight for the drug substance is 801.91 (dihydrate).  The drug substance is white to off-white powder with very low water solubility. Paritaprevir has the following molecular structure:</p>
                  <rendermultimedia referencedobject="g105373291418933848"></rendermultimedia>
                  <p id="p102646291393950056">
                     <content stylecode="underline">Ritonavir</content>
                  </p>
                  <p id="p974612291393950074">The chemical name of ritonavir is [5S-(5R*,8R*,10R*,11R*)]10-Hydroxy-2-methyl-5-(1-methyethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid,5-thiazolylmethyl ester. The molecular formula is C<sub>37</sub>H<sub>48</sub>N<sub>6</sub>O<sub>5</sub>S<sub>2</sub> and the molecular weight for the drug substance is 720.95. The drug substance is white to off white to light tan powder practically insoluble in water and freely soluble in methanol and ethanol. Ritonavir has the following molecular structure:</p>
                  <rendermultimedia referencedobject="g105073291418933910"></rendermultimedia>
                  <p id="p94893291416543082">
                     <content stylecode="underline">Ombitasvir, Paritaprevir, Ritonavir Fixed-Dose Combination Tablets </content>
                  </p>
                  <p id="p97294291393950253">Ombitasvir, paritaprevir, and ritonavir film-coated tablets are co-formulated immediate release tablets. The tablet contains copovidone, K value 28, vitamin E polyethylene glycol succinate, propylene glycol monolaurate Type I, sorbitan monolaurate, colloidal silicon dioxide/colloidal anhydrous silica, sodium stearyl fumarate, polyvinyl alcohol, polyethylene glycol 3350/macrogol 3350, talc, titanium dioxide, and iron oxide red. The strength for the tablet is 12.5 mg ombitasvir, 75 mg paritaprevir, 50 mg ritonavir.</p>
                  <p id="p135832291393950298">
                     <content stylecode="underline">Dasabuvir</content>
                  </p>
                  <p id="p136129291393950320">The chemical name of dasabuvir is Sodium 3-(3-<content stylecode="italics">tert</content>-butyl-4-methoxy-5-{6-[(methylsulfonyl)amino]naphthalene-2-yl}phenyl)-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-ide hydrate (1:1:1).&nbsp;The molecular formula is C<sub>26</sub>H<sub>26</sub>N<sub>3</sub>O<sub>5</sub>S•Na•H<sub>2</sub>O (salt, hydrate) and the molecular weight of the drug substance is 533.57 (salt, hydrate).&nbsp;The drug substance is white to pale yellow to pink powder, slightly soluble in water and very slightly soluble in methanol and isopropyl alcohol. Dasabuvir has the following molecular structure:</p>
                  <rendermultimedia referencedobject="g430533291418933953"></rendermultimedia>
                  <p id="p138284291393950497">Dasabuvir is formulated as a 250 mg film-coated, immediate release tablet containing microcrystalline cellulose (D50-100 um), microcrystalline cellulose (D50-50 um), lactose monohydrate, copovidone, croscarmellose sodium, colloidal silicon dioxide/anhydrous colloidal silica, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol 3350/macrogol 3350, talc, and iron oxide yellow, iron oxide red and iron oxide black. Each tablet contains 270.3 mg dasabuvir sodium monohydrate equivalent to 250 mg dasabuvir.</p>
               </text></div>
<span id="VIEKIRA_PAK_collapsableElement_" class="safetySubheading"></span><div id="" class="safetySubdescription"></div>
<span id="VIEKIRA_PAK_collapsableElement_" class="safetySubheading"></span><div id="" class="safetySubdescription"></div>
<span id="VIEKIRA_PAK_collapsableElement_" class="safetySubheading"></span><div id="" class="safetySubdescription"></div>
<span id="VIEKIRA_PAK_collapsableElement_" class="safetySubheading"></span><div id="" class="safetySubdescription"></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34090-1">
<div class="drugSubheadings">
<span id="VIEKIRA_PAK_34090-1" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>12 CLINICAL PHARMACOLOGY</div>
<div id="VIEKIRA_PAK_previewText_34090-1" class="previewText"><span>...</span></div>
</div>
<div id="VIEKIRA_PAK_collapsableElement_34090-1" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"></div>
<span id="VIEKIRA_PAK_collapsableElement_12_1" class="safetySubheading">12.1 Mechanism of Action</span><div id="43679-0" class="safetySubdescription"><text>
                        <p id="p407157291409085467">VIEKIRA PAK combines three direct-acting hepatitis C virus antiviral agents with distinct mechanisms of action <content stylecode="italics">[see Microbiology (<a href="#section_12.4">12.4</a>)]</content>.</p>
                        <p id="p361151291395774328">Ritonavir is not active against HCV. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of paritaprevir and overall drug exposure (i.e., area under the curve).</p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_12_2" class="safetySubheading">12.2 Pharmacodynamics</span><div id="43681-6" class="safetySubdescription"><text>
                        <p id="p2050224">
                           <content stylecode="underline">Cardiac Electrophysiology</content>
                        </p>
                        <p id="p138732291393950813">The effect of a combination of ombitasvir, paritaprevir, ritonavir, and dasabuvir on QTc interval was evaluated in a randomized, double blind, placebo and active-controlled (moxifloxacin 400 mg) 4-way crossover thorough QT study in 60 healthy subjects. At concentrations approximately 6, 1.8 and 2 times the therapeutic concentrations of paritaprevir, ombitasvir, and dasabuvir, the combination did not prolong QTc to any clinically relevant extent. </p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_12_3" class="safetySubheading">12.3 Pharmacokinetics</span><div id="43682-4" class="safetySubdescription"><text>
                        <p id="p484271291413821179">
                           <content stylecode="underline">Absorption</content>
                        </p>
                        <p id="p105263291413821197">Ombitasvir, paritaprevir, ritonavir and dasabuvir were absorbed after oral administration with mean T<sub>max</sub> of approximately 4 to 5 hours. While ombitasvir and dasabuvir exposures increased in a dose proportional manner, paritaprevir and ritonavir exposures increased in a more than dose proportional manner. Accumulation is minimal for ombitasvir and dasabuvir and approximately 1.5- to 2-fold for ritonavir and paritaprevir. Steady state exposures are achieved after approximately 12 days of dosing.</p>
                        <p id="p105283291413821252">The absolute bioavailability of dasabuvir estimated to be approximately 70%. The absolute bioavailability of ombitasvir, paritaprevir, and ritonavir was not evaluated.</p>
                        <p id="p105243291413821258">Based on the population pharmacokinetic analysis, the median steady-state AUC<sub>0-24 </sub>for ombitasvir, paritaprevir and ritonavir were 1000, 2220 and 6180 ng•hr/mL, respectively, and the median steady-state AUC<sub>0-12 </sub>for dasabuvir was 3240 ng•hr/mL when VIEKIRA PAK was administered to HCV-infected subjects. Median steady-state C<sub>max</sub> for ombitasvir, paritaprevir, ritonavir and dasabuvir were 68, 262, 682 and 667 ng/mL, respectively, when VIEKIRA PAK was administered to HCV-infected subjects.</p>
                        <p id="p484311291413821267">
                           <content stylecode="italics">Effects of Food on Oral Absorption</content>
                        </p>
                        <p id="p107593291413821307">Relative to fasting conditions, administration of ombitasvir, paritaprevir, ritonavir, and dasabuvir with a moderate fat meal (approximately 600 Kcal, 20-30% calories from fat) increased the mean AUC by 82%, 211%, 49%, and 30%, respectively.</p>
                        <p id="p107643291413821322">Relative to fasting conditions, administration of ombitasvir, paritaprevir, ritonavir, and dasabuvir with a high fat meal (approximately 900 Kcal, 60% calories from fat) increased the mean AUC by 76%, 180%, 44%, and 22%, respectively.</p>
                        <p id="p107673291413821334">Ombitasvir, paritaprevir, ritonavir, and dasabuvir should always be administered with a meal.</p>
                        <p id="p425184291423070290">
                           <content stylecode="underline">Distribution</content>
                        </p>
                        <p id="p107733291413821360">
                           <content stylecode="italics">Ombitasvir:</content> Ombitasvir was approximately 99.9% bound to human plasma proteins over a concentration range of 0.09 to 9 µg per mL.  The mean blood-to-plasma concentration ratio was 0.49.  The apparent volume of distribution (V/F) was 50.1 L.</p>
                        <p id="p107783291413821375">
                           <content stylecode="italics">Paritaprevir:</content> Paritaprevir was approximately 97 to 98.6% bound to human plasma proteins over a concentration range of 0.08 to 8 µg per mL. The mean blood-to-plasma concentration ratio was 0.7. The apparent volume of distribution (V/F) was 16.7 L.</p>
                        <p id="p107843291413821388">
                           <content stylecode="italics">Ritonavir:</content> Ritonavir was greater than 99% bound to human plasma proteins over a concentration range of 0.007 to 22 µg per mL.  The mean blood-to-plasma concentration ratio was 0.6. The apparent volume of distribution (V/F) was 21.5 L.</p>
                        <p id="p107903291413821402">
                           <content stylecode="italics">Dasabuvir:</content> Dasabuvir was greater than 99.5% bound to human plasma proteins over a concentration range of 0.05 to 5 µg per mL. The mean blood-to-plasma concentration ratio was 0.7. The apparent volume of distribution (V/F) was 396 L.</p>
                        <p id="p483944291413821426">
                           <content stylecode="underline">Metabolism</content>
                        </p>
                        <p id="p110083291413821437">
                           <content stylecode="italics">Ombitasvir:</content> Ombitasvir is predominantly metabolized by amide hydrolysis followed by oxidative metabolism. </p>
                        <p id="p110133291413821449">
                           <content stylecode="italics">Paritaprevir:</content> Paritaprevir is predominantly metabolized by CYP3A4 and to a lesser extent by CYP3A5.</p>
                        <p id="p110193291413821465">
                           <content stylecode="italics">Ritonavir:</content> Ritonavir is predominantly metabolized by CYP3A, and to a lesser extent, by CYP2D6.</p>
                        <p id="p110253291413821475">
                           <content stylecode="italics">Dasabuvir:</content> Dasabuvir is predominantly metabolized by CYP2C8, and to a lesser extent by CYP3A.</p>
                        <p id="p1614813291393954738">
                           <content stylecode="underline">Elimination</content>
                        </p>
                        <p id="p110288291413576223">
                           <content stylecode="italics">Ombitasvir:</content> Following a single dose administration of <sup>14</sup>C-ombitasvir, approximately 90.2% of the radioactivity was recovered in feces with limited radioactivity (1.91%) in urine; unchanged ombitasvir accounted for 87.8% of the radioactivity in the feces and 0.03% in the urine. The mean elimination half-life of ombitasvir was approximately 21 to 25 hours. </p>
                        <p id="p507325291413576241">
                           <content stylecode="italics">Paritaprevir:</content> Following a single dose administration of <sup>14</sup>C-paritaprevir co-dosed with 100 mg of ritonavir, approximately 88% of the radioactivity was recovered in feces with limited radioactivity (8.8%) in urine; unchanged paritaprevir accounted for 1.1% of the radioactivity in the feces and 0.05% in the urine.  The mean plasma half-life of paritaprevir was approximately 5.5 hours.</p>
                        <p id="p110479291413576257">
                           <content stylecode="italics">Ritonavir: </content>Following dosing of ritonavir with ombitasvir and  paritaprevir, mean plasma half-life of ritonavir was approximately 4 hours. Following a single 600 mg dose of <sup>14</sup>C-ritonavir oral solution, 86.4% of the radioactivity was recovered in the feces and 11.3% of the dose was excreted in the urine.</p>
                        <p id="p110547291413576274">
                           <content stylecode="italics">Dasabuvir: </content>Following a single dose administration of <sup>14</sup>C-dasabuvir, approximately 94.4% of the radioactivity was recovered in feces with limited radioactivity (approximately 2%) in urine; unchanged dasabuvir accounted for 26% of the radioactivity in the feces and 0.03% in the urine. The mean plasma half-life of dasabuvir was approximately 5.5 to 6 hours.</p>
                        <p id="p112996291413576294">Ombitasvir, paritaprevir, ritonavir, and dasabuvir do not inhibit organic anion transporter (OAT1) <content stylecode="italics">in vivo </content>and based on <content stylecode="italics">in vitro</content> data, are not expected to inhibit organic cation transporter (OCT2), organic anion transporter (OAT3), or multidrug and toxin extrusion proteins (MATE1 and MATE2K) at clinically relevant concentrations.</p>
                        <p id="p168971291393955279">
                           <content stylecode="underline">Specific Populations</content>
                        </p>
                        <p id="p169222291393955402">
                           <content stylecode="italics">Hepatic Impairment</content>
                        </p>
                        <p id="p122905291413324281">The single dose pharmacokinetics of ombitasvir, paritaprevir, ritonavir and dasabuvir were evaluated in non-HCV infected subjects with mild hepatic impairment (Child-Pugh Category A; score of 5-6), moderate hepatic impairment (Child-Pugh Category B, score of 7-9) and severe hepatic impairment (Child-Pugh Category C, score of 10-15).</p>
                        <p id="p122925291413324284">Relative to subjects with normal hepatic function, ombitasvir, paritaprevir and ritonavir AUC values decreased  by 8%, 29% and 34%,  respectively, and dasabuvir AUC values increased by 17%  in subjects with mild hepatic impairment.</p>
                        <p id="p122945291413324287">Relative to subjects with normal hepatic function, ombitasvir, ritonavir and dasabuvir AUC values decreased by 30%, 30% and 16%, respectively, and paritaprevir AUC values increased by 62% in subjects with moderate hepatic impairment.</p>
                        <p id="p535291291444938624">Relative to subjects with normal hepatic function, paritaprevir, ritonavir and dasabuvir AUC values increased by 945%, 13%, and 325% respectively, and ombitasvir AUC values decreased by 54% in subjects with severe hepatic impairment <content stylecode="italics">[see Dosage and Administration (<a href="#section_2.4">2.4</a>), Contraindications (<a href="#section_4">4</a>), Warnings and Precautions (<a href="#section_5.1">5.1</a>) and Use in Specific Populations (<a href="#section_8.6">8.6</a>)]</content>.</p>
                        <p id="p168982291393955294">
                           <content stylecode="italics">Renal Impairment</content>
                        </p>
                        <p id="p3716312291413324584">The single dose pharmacokinetics of ombitasvir, paritaprevir, ritonavir and dasabuvir were evaluated in non-HCV infected subjects with mild (CL<sub>cr</sub>: 60 to 89 mL/min), moderate (CL<sub>cr</sub>: 30 to 59 mL/min), and severe (CL<sub>cr</sub>: 15 to 29 mL/min) renal impairment.</p>
                        <p id="p122883291413324587">Overall, changes in exposure of ombitasvir, paritaprevir, ritonavir and dasabuvir in non-HCV infected subjects with mild-, moderate- and severe renal impairment are not expected to be clinically relevant.  Pharmacokinetic data are not available on the use of VIEKIRA PAK in non-HCV infected subjects with End Stage Renal Disease (ESRD).</p>
                        <p id="p123245291413324589">Relative to subjects with normal renal function, paritaprevir, ritonavir and dasabuvir AUC values increased by 19%, 42% and 21%, respectively, while ombitasvir AUC values were unchanged in subjects with mild renal impairment.</p>
                        <p id="p123265291413324595">Relative to subjects with normal renal function, paritaprevir, ritonavir and dasabuvir AUC values increased by 33%, 80% and 37%, respectively, while ombitasvir AUC values were unchanged in subjects with moderate renal impairment.</p>
                        <p id="p123285291413324598">Relative to subjects with normal renal function, paritaprevir, ritonavir and dasabuvir AUC values increased by 45%, 114% and 50%, respectively, while ombitasvir AUC values were unchanged in subjects with severe renal impairment <content stylecode="italics">[see Use in Specific Populations (<a href="#section_8.7">8.7</a>)]</content>.</p>
                        <p id="p169443291393962438">
                           <content stylecode="italics">Pediatric Population</content>
                        </p>
                        <p id="p4276210291396741680">The pharmacokinetics of VIEKIRA PAK in pediatric patients less than 18 years of age has not been established <content stylecode="italics">[see Use in Specific Populations (<a href="#section_8.4">8.4</a>)]</content>.</p>
                        <p id="p171552291393962454">
                           <content stylecode="italics">Sex</content>
                        </p>
                        <p id="p504531291396741717">No dose adjustment is recommended based on sex or body weight.</p>
                        <p id="p504542291396741734">
                           <content stylecode="italics">Race/Ethnicity</content>
                        </p>
                        <p id="p504621291396741758">No dose adjustment is recommended based on race or ethnicity.</p>
                        <p id="p504632291396741772">
                           <content stylecode="italics">Age</content>
                        </p>
                        <p id="p504701291396741797">No dose adjustment is recommended in geriatric patients <content stylecode="italics">[see Use in Specific Populations (<a href="#section_8.5">8.5</a>)]</content>.</p>
                        <p id="p171563291393962479">
                           <content stylecode="underline">Drug Interaction Studies</content>
                        </p>
                        <p id="p171632291393962492">
                           <content stylecode="italics">See also Contraindications (<a href="#section_4">4</a>), Warnings and Precautions (<a href="#section_5.4">5.4</a>), Drug Interactions (<a href="#section_7">7</a>)</content>
                        </p>
                        <p id="p133273291413324967">The effects of drugs discussed in <a href="#table_5">Table 5</a> on the exposures of the individual components of VIEKIRA PAK are shown in <a href="#table_6">Table 6</a>. For information regarding clinical recommendations, see <content stylecode="italics">Drug Interactions (<a href="#section_7">7</a>)</content>.</p>
                        <table id="table_6" border="1" frame="box" width="100%">
                           <caption>Table 6. Drug Interactions: Change in Pharmacokinetic Parameters of the Individual Components of VIEKIRA PAK in the Presence of Co-administered Drug</caption>
                           <colgroup>
                              <col width="15%">
                              <col width="13%">
                              <col width="4%">
                              <col width="13%">
                              <col width="17%">
                              <col width="17%">
                              <col width="17%">
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">
                                    <content stylecode="bold">Co-administered</content>
                                    <br>
                                    <content stylecode="bold"> Drug</content>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">
                                    <content stylecode="bold">Dose of Co-</content>
                                    <br>
                                    <content stylecode="bold">administered</content>
                                    <br>
                                    <content stylecode="bold"> Drug (mg)</content>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">
                                    <content stylecode="bold">n</content>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">
                                    <content stylecode="bold">DAA</content>
                                 </td>
                                 <td stylecode="Botrule Rrule" colspan="3" align="center" valign="top">
                                    <content stylecode="bold">Ratio (with/without co-administered drug) of</content>
                                    <br>
                                    <content stylecode="bold"> DAA Pharmacokinetic Parameters (90% CI);</content>
                                    <br>
                                    <content stylecode="bold">  No Effect = 1.00</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">&nbsp;</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">&nbsp;</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">&nbsp;</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">&nbsp;</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">
                                    <content stylecode="bold">C<sub>max</sub>
                                    </content>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">
                                    <content stylecode="bold">AUC</content>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">
                                    <content stylecode="bold">C<sub>min</sub>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Alprazolam</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">0.5 single<br>dose</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">12</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.98<br>(0.93, 1.04)</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">1.00<br>(0.96, 1.04)</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.98<br>(0.93, 1.04)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.91<br>(0.64, 1.31)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.96<br>(0.73, 1.27)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.12<br>(1.02, 1.23)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.92<br>(0.84, 1.02)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.96<br>(0.89, 1.03)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.01<br>(0.94, 1.09)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.93<br>(0.83, 1.04)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.98<br>(0.87, 1.11)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.00<br>(0.87, 1.15)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Amlodipine</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">5 single dose</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">14</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">1.00<br>(0.95, 1.06)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.00<br>(0.97, 1.04)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.00<br>(0.97, 1.04)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.77<br>(0.64, 0.94)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.78<br>(0.68, 0.88)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.88<br>(0.80, 0.95)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.96<br>(0.87, 1.06)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.93<br>(0.89, 0.98)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.95<br>(0.89, 1.01)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">1.05<br>(0.97, 1.14)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.01<br>(0.96, 1.06)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.95<br>(0.89, 1.01)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Atazanavir/<br>ritonavir<sup>a</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Atazanavir 300<br>and ritonavir 100<br> once daily in the evening</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">11</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.83<br>(0.72, 0.96)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.90<br>(0.78, 1.02)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.00<br>(0.89, 1.13)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center">2.19<br>(1.61, 2.98)</td>
                                 <td stylecode="Botrule Rrule" align="center">3.16<br>(2.40, 4.17)</td>
                                 <td stylecode="Botrule Rrule" align="center">11.95<br>(8.94, 15.98)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.60<br>(1.38, 1.86)</td>
                                 <td stylecode="Botrule Rrule" align="center">3.18<br>(2.74, 3.69)</td>
                                 <td stylecode="Botrule Rrule" align="center">24.65<br>(18.64, 32.60)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.81<br>(0.73, 0.91)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.81<br>(0.71, 0.92)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.80<br>(0.65, 0.98)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Carbamazepine</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">200 once daily<br>followed by<br> 200 twice daily</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">12</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.69<br>(0.61, 0.78)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.69<br>(0.64, 0.74)</td>
                                 <td stylecode="Botrule Rrule" align="center">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.34<br>(0.25, 0.48)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.30<br>(0.23, 0.38)</td>
                                 <td stylecode="Botrule Rrule" align="center">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.17<br>(0.12, 0.24)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.13<br>(0.09, 0.17)</td>
                                 <td stylecode="Botrule Rrule" align="center">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.45<br>(0.41, 0.50)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.30<br>(0.28, 0.33)</td>
                                 <td stylecode="Botrule Rrule" align="center">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Cyclosporine</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">30 single dose<sup>b</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">10</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.99<br>(0.92, 1.07)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.08<br>(1.05, 1.11)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.15<br>(1.08, 1.23)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.44<br>(1.16, 1.78)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.72<br>(1.49, 1.99)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.85<br>(1.58, 2.18)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.90<br>(0.78, 1.04)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.11<br>(1.04, 1.19)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.49<br>(1.28, 1.74)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.66<br>(0.58, 0.75)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.70<br>(0.65, 0.76)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.76<br>(0.71, 0.82)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Darunavir<sup>c</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">800 once daily</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">9</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.86<br>(0.77, 0.95)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.86<br>(0.79, 0.94)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.87<br>(0.82, 0.92)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.54<br>(1.14, 2.09)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.29<br>(1.04, 1.61)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.30<br>(1.09, 1.54)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.84<br>(0.72, 0.98)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.85<br>(0.78, 0.93)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.07<br>(0.93, 1.23)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.10<br>(0.88, 1.37)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.94<br>(0.78, 1.14)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.90<br>(0.76, 1.06)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Darunavir/<br>ritonavir<sup>d</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Darunavir<br>600 twice daily and<br> ritonavir 100 once daily<br> in the evening </td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">7</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.76<br>(0.65, 0.88)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.73<br>(0.66, 0.80)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.73<br>(0.64, 0.83)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.70<br>(0.43, 1.12)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.59<br>(0.44, 0.79)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.83<br>(0.69, 1.01)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.61<br>(1.30, 2.00)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.28<br>(1.12, 1.45)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.88<br>(0.79, 0.99)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.84<br>(0.67, 1.05)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.73<br>(0.62, 0.86)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.54<br>(0.49, 0.61)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Darunavir/<br>ritonavir<sup>e</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Darunavir<br>800 and<br> ritonavir 100<br>  once daily in the<br> evening</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">12</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.87<br>(0.82, 0.93)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.87<br>(0.81, 0.93)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.87<br>(0.80, 0.95)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.70<br>(0.50, 0.99)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.81<br>(0.60, 1.09)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.59<br>(1.23, 2.05)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.19<br>(1.06, 1.33)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.70<br>(1.54, 1.88)</td>
                                 <td stylecode="Botrule Rrule" align="center">14.15<br>(11.66, 17.18)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.75<br>(0.64, 0.88)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.72<br>(0.64, 0.82)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.65<br>(0.58, 0.72)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Ethinyl estradiol/<br>Norgestimate</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Ethinyl<br>estradiol<br>0.035 and<br>Norgestimate<br>0.25 once daily</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">7<sup>f</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.05<br>(0.81, 1.35)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.97<br>(0.81, 1.15)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.00<br>(0.88, 1.12)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.70<br>(0.40, 1.21)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.66<br>(0.42, 1.04)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.87<br>(0.67, 1.14)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.80<br>(0.53, 1.21)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.71<br>(0.54, 0.94)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.79<br>(0.68, 0.93)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.51<br>(0.22, 1.18)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.48<br>(0.23, 1.02)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.53<br>(0.30, 0.95)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Furosemide</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">20 single dose</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">12</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.14<br>(1.03, 1.26)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.07<br>(1.01, 1.12)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.12<br>(1.08, 1.16)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.93<br>(0.63, 1.36)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.92<br>(0.70, 1.21)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.26<br>(1.16, 1.38)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.10<br>(0.96, 1.27)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.04<br>(0.92, 1.18)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.07<br>(0.99, 1.17)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.12<br>(0.96, 1.31)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.09<br>(0.96, 1.23)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.06<br>(0.98, 1.14)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Gemfibrozil<sup>g</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">600 twice daily</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">11</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center">NA</td>
                                 <td stylecode="Botrule Rrule" align="center">NA</td>
                                 <td stylecode="Botrule Rrule" align="center">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.21<br>(0.94, 1.57)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.38<br>(1.18, 1.61)</td>
                                 <td stylecode="Botrule Rrule" align="center">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.84<br>(0.69, 1.03)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.90<br>(0.78, 1.04)</td>
                                 <td stylecode="Botrule Rrule" align="center">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center">2.01<br>(1.71, 2.38)</td>
                                 <td stylecode="Botrule Rrule" align="center">11.25<br>(9.05, 13.99)</td>
                                 <td stylecode="Botrule Rrule" align="center">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Ketoconazole</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">400 once daily</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">12</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.98<br>(0.90, 1.06)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.17<br>(1.11, 1.24)</td>
                                 <td stylecode="Botrule Rrule" align="center">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.37<br>(1.11, 1.69)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.98<br>(1.63, 2.42)</td>
                                 <td stylecode="Botrule Rrule" align="center">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.27<br>(1.04, 1.56)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.57<br>(1.36, 1.81)</td>
                                 <td stylecode="Botrule Rrule" align="center">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.16<br>(1.03, 1.32)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.42<br>(1.26, 1.59)</td>
                                 <td stylecode="Botrule Rrule" align="center">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Lopinavir/<br>ritonavir</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">400/100 twice daily</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">6</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.14<br>(1.01, 1.28)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.17<br>(1.07, 1.28)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.24<br>(1.14, 1.34)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center">2.04<br>(1.30, 3.20)</td>
                                 <td stylecode="Botrule Rrule" align="center">2.17<br>(1.63, 2.89)</td>
                                 <td stylecode="Botrule Rrule" align="center">2.36<br>(1.00, 5.55)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.55<br>(1.16, 2.09)</td>
                                 <td stylecode="Botrule Rrule" align="center">2.05<br>(1.49, 2.81)</td>
                                 <td stylecode="Botrule Rrule" align="center">5.25<br>(3.33, 8.28)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.99<br>(0.75, 1.31)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.93<br>(0.75, 1.15)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.68<br>(0.57, 0.80)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Lopinavir/<br>ritonavir<sup>h</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">800/200 once daily</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">12</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.87<br>(0.83, 0.92)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.97<br>(0.94, 1.02)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.11<br>(1.06, 1.16)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.99<br>(0.79, 1.25)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.87<br>(1.40, 2.52)</td>
                                 <td stylecode="Botrule Rrule" align="center">8.23<br>(5.18, 13.07)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.57<br>(1.34, 1.83)</td>
                                 <td stylecode="Botrule Rrule" align="center">2.62<br>(2.32, 2.97)</td>
                                 <td stylecode="Botrule Rrule" align="center">19.46<br>(15.93, 23.77)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.56<br>(0.47, 0.66)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.54<br>(0.46, 0.65)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.47<br>(0.39, 0.58)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Omeprazole</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">40 once daily</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">11</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.02<br>(0.95, 1.09)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.05<br>(0.98, 1.12)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.04<br>(0.98, 1.11)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.19<br> (1.04, 1.36)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.18<br>(1.03, 1.37)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.92<br>(0.76, 1.12)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.04<br>(0.96, 1.12)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.02<br>(0.97, 1.08)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.97<br>(0.89, 1.05)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.13<br>(1.03, 1.25)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.08<br>(0.98, 1.20)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.05<br>(0.93, 1.19)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Pravastatin</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">10 once daily</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">12</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.95<br>(0.89, 1.02)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.94<br>(0.89, 0.99)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.94<br>(0.89, 0.99)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.96<br>(0.69, 1.32)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.13<br>(0.92, 1.38)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.39<br>(1.21, 1.59)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.89<br>(0.73, 1.09)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.95<br>(0.86, 1.05)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.08<br>(0.98, 1.19)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.00<br>(0.87, 1.14)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.96<br>(0.85, 1.09)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.03<br>(0.91, 1.15)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Rosuvastatin</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">5 once daily</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">11</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.92<br>(0.82, 1.04)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.89<br>(0.83, 0.95)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.88<br>(0.83, 0.94)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.59<br>(1.13, 2.23)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.52<br>(1.23, 1.90)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.43<br>(1.22, 1.68)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.98<br>(0.84, 1.15)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.02<br>(0.93, 1.12)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.00<br>(0.90, 1.12)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.07<br>(0.92, 1.24)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.08<br>(0.92, 1.26)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.15<br>(1.05, 1.25)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Rilpivirine</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">25 once daily<br>(morning)<sup>i</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">10</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.11<br>(1.02, 1.20)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.09<br>(1.04, 1.14)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.05<br>(1.01, 1.08)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.30<br>(0.94, 1.81)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.23<br>(0.93, 1.64)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.95<br>(0.84, 1.07)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.10<br>(0.98, 1.24)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.08<br>(0.93, 1.27)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.97<br>(0.91, 1.04)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center">1.18<br>(1.02, 1.37)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.17<br>(0.99, 1.38)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.10<br>(0.89, 1.37)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">Tacrolimus</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">2 single dose</td>
                                 <td stylecode="Botrule Rrule" rowspan="4" align="center" valign="top">12</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ombitasvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.93<br>(0.88, 0.99)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.94<br>(0.89, 0.98)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.94<br>(0.91, 0.96)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">paritaprevir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.57<br>(0.42, 0.78)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.66<br>(0.54, 0.81)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.73<br>(0.66, 0.80)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.76<br>(0.63, 0.91)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.87<br>(0.79, 0.97)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.03<br>(0.89, 1.19)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">dasabuvir</td>
                                 <td stylecode="Botrule Rrule" align="center">0.85<br>(0.73, 0.98)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.90<br>(0.80, 1.02)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.01<br>(0.91, 1.11)</td>
                              </tr>
                              <tr>
                                 <td colspan="7" align="left">
                                    <ul ultype="ordered" id="l563493291413384310" stylecode="LittleAlpha">
                                       <li>Atazanavir plus 100 mg ritonavir administered in the evening, 12 hours after morning dose of VIEKIRA PAK.</li>
                                       <li>30 mg cyclosporine was administered with VIEKIRA PAK in the test arm and 100 mg cyclosporine was administered in the reference arm without VIEKIRA PAK.</li>
                                       <li>Darunavir administered with VIEKIRA PAK in the morning was compared to darunavir administered with 100 mg ritonavir in the morning.</li>
                                       <li>Darunavir administered with VIEKIRA PAK in the morning and with 100 mg ritonavir in the evening was compared to darunavir administered with 100 mg ritonavir in the morning and evening.</li>
                                       <li>Darunavir plus 100 mg ritonavir administered in the evening, 12 hours after the morning dose of VIEKIRA PAK compared to darunavir administered with 100 mg ritonavir in the evening.</li>
                                       <li>N=3 for dasabuvir.</li>
                                       <li>Study was conducted with paritaprevir, ritonavir and dasabuvir.</li>
                                       <li>Lopinavir/ritonavir administered in the evening, 12 hours after morning dose of VIEKIRA PAK.</li>
                                       <li>Similar increases were observed when rilpivirine was dosed in the evening with food or 4 hours after food.</li>
                                    </ul>
                                    <p id="p573584291413384471">NA: not available/not applicable; DAA: Direct-acting antiviral agent; CI: Confidence interval</p>
                                    <p id="p573445291413384485">Doses of ombitasvir, paritaprevir, and ritonavir were 25 mg, 150 mg and 100 mg. Doses of dasabuvir were 250 mg or 400 mg (both doses showed similar exposures).</p>
                                    <p id="p573632291413384498">Ombitasvir, paritaprevir and ritonavir were dosed once daily and dasabuvir was dosed twice daily in all the above studies except studies with gemfibrozil, ketoconazole and carbamazepine that used single doses.</p>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <p id="p182042291394476004">
                           <a href="#table_7">Table 7</a> summarizes the effects of VIEKIRA PAK on the pharmacokinetics of co-administered drugs which showed clinically relevant changes. For information regarding clinical recommendations, see <content stylecode="italics">Drug Interactions (<a href="#section_7">7</a>)</content>.</p>
                        <table id="table_7" frame="box" width="100%">
                           <caption>Table 7. Drug Interactions: Change in Pharmacokinetic Parameters for Co-administered Drug in the Presence of VIEKIRA PAK</caption>
                           <colgroup>
                              <col width="15%">
                              <col width="15%">
                              <col width="9%">
                              <col width="20%">
                              <col width="20%">
                              <col width="20%">
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">
                                    <content stylecode="bold">Co-administered</content>
                                    <br>
                                    <content stylecode="bold">Drug</content>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">
                                    <content stylecode="bold">Dose of Co-administered</content>
                                    <br>
                                    <content stylecode="bold">Drug (mg)</content>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">
                                    <content stylecode="bold">&nbsp;n&nbsp;</content>
                                 </td>
                                 <td stylecode="Botrule" colspan="3" align="center" valign="top">
                                    <content stylecode="bold">Ratio (with/without VIEKIRA PAK) of Co-administered Drug Pharmacokinetic Parameters</content>
                                    <br>
                                    <content stylecode="bold">(90% CI); No Effect = 1.00</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top"></td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">&nbsp;</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">&nbsp;</td>
                                 <td stylecode="Botrule" align="center" valign="top">
                                    <content stylecode="bold">C<sub>max</sub>
                                    </content>
                                 </td>
                                 <td stylecode="Botrule" align="center" valign="top">
                                    <content stylecode="bold">AUC</content>
                                 </td>
                                 <td stylecode="Botrule" align="center" valign="top">
                                    <content stylecode="bold">C<sub>min</sub>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Alprazolam</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.5 single dose</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">12</td>
                                 <td stylecode="Botrule Rrule" align="center">1.09<br>  (1.03, 1.15)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.34<br> (1.15, 1.55)</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Amlodipine</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">5 single dose</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">14</td>
                                 <td stylecode="Botrule Rrule" align="center">1.26<br> (1.11, 1.44)</td>
                                 <td stylecode="Botrule Rrule" align="center">2.57<br> (2.31, 2.86)  </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Atazanavir/ritonavir<sup>a</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Atazanavir 300 and ritonavir 100 once daily in the evening</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">12</td>
                                 <td stylecode="Botrule Rrule" align="center">1.02 <br>(0.92, 1.13)<sup>b</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">1.19 <br>(1.11, 1.28)<sup>b</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">1.68 <br>(1.44, 1.95)<sup>b</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Buprenorphine</td>
                                 <td stylecode="Botrule Rrule" rowspan="3" align="center" valign="top">Buprenorphine: 4 to 24  once daily and Naloxone 1 to 6 once daily</td>
                                 <td stylecode="Botrule Rrule" rowspan="3" align="center" valign="top">10</td>
                                 <td stylecode="Botrule Rrule" align="center">2.18 <br>(1.78, 2.68)<sup>c</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">2.07<br>(1.78, 2.40)<sup>c</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">3.12 <br>(2.29, 4.27)<sup>c</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Norbuprenorphine</td>
                                 <td stylecode="Lrule Botrule Rrule" align="center">2.07 <br>(1.42, 3.01)<sup>c</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">1.84 <br>(1.30, 2.60)<sup>c</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">2.10<br>(1.49, 2.97)<sup>c</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Naloxone</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">1.18 <br>(0.81, 1.73)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.28 <br>(0.92, 1.79)<sup>c</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Carbamazepine</td>
                                 <td stylecode="Botrule Rrule" rowspan="2" align="center" valign="top">200  once daily followed by 200 twice daily</td>
                                 <td stylecode="Botrule Rrule" rowspan="2" align="center" valign="top">12</td>
                                 <td stylecode="Botrule Rrule" align="center">1.10 <br>(1.07, 1.14)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.17 <br>(1.13, 1.22)</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">1.35<br>(1.27, 1.45)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Carbamazepine’s metabolite, carbamazepine-10,11-epoxide (CBZE)</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.84 <br>(0.82, 0.87)</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.75 <br>(0.73, 0.77)</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.57 <br>(0.54, 0.61)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Cyclosporine</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">30 single dose<sup>d</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">10</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">1.01<br> (0.85, 1.20)<sup>c</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top"> 5.82<br> (4.73, 7.14)<sup>c</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">15.80 <br>(13.81, 18.09)<sup>c</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Darunavir<sup>e</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">800 once daily</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">8</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.92 <br>(0.87, 0.98)<sup>b</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.76 <br>(0.71, 0.82)<sup>b</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.52 <br>(0.47, 0.58)<sup>b</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Darunavir/ritonavir<sup>f</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Darunavir 600 twice daily and ritonavir 100 once daily in the evening</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">7</td>
                                 <td stylecode="Botrule Rrule" align="center">0.87 <br>(0.79, 0.96)<sup>b</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">0.80 <br>(0.74, 0.86)<sup>b</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.57 <br>(0.48, 0.67)<sup>b</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Darunavir/ritonavir<sup>g</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Darunavir 800 and ritonavir 100  once daily in the evening</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">10</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.79<br> (0.70, 0.90)<sup>b</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">1.34<br> (1.25, 1.43)<sup>b</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.54<br> (0.48, 0.62)<sup>b</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Ethinyl Estradiol</td>
                                 <td stylecode="Botrule Rrule" rowspan="3" align="center" valign="top">Ethinyl estradiol 0.035 and Norgestimate 0.25 once daily</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">8</td>
                                 <td stylecode="Botrule Rrule" align="center">1.16 <br>(0.90, 1.50)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.06 <br>(0.96, 1.17)</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">1.12 <br>(0.94, 1.33)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Norelgestromin</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">9</td>
                                 <td stylecode="Botrule Rrule" align="center">2.01 <br>(1.77, 2.29)</td>
                                 <td stylecode="Botrule Rrule" align="center">2.60 <br>(2.30, 2.95)</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">3.11 <br>(2.51, 3.85)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Norgestrel</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">9</td>
                                 <td stylecode="Botrule Rrule" align="center">2.26 <br>(1.91, 2.67)</td>
                                 <td stylecode="Botrule Rrule" align="center">2.54 <br>(2.09, 3.09)</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">2.93 <br>(2.39, 3.57)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Furosemide</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">20 single dose</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">12</td>
                                 <td stylecode="Botrule Rrule" align="center">1.42<br>(1.17, 1.72)</td>
                                 <td stylecode="Botrule Rrule" align="center">1.08<br>(1.00, 1.17)</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Ketoconazole</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">400 once daily</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">12</td>
                                 <td stylecode="Botrule Rrule" align="center">1.15<br> (1.09, 1.21)</td>
                                 <td stylecode="Botrule Rrule" align="center">2.17<br> (2.05, 2.29)</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Lopinavir/ritonavir</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">400/100 twice daily</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">6</td>
                                 <td stylecode="Botrule Rrule" align="center">0.87 <br>(0.76, 0.99)<sup>b</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">0.94 <br>(0.81, 1.10)<sup>b</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">1.15 <br>(0.93, 1.42)<sup>b</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Lopinavir/ritonavir<sup>h</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">800/200 once daily</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">12</td>
                                 <td stylecode="Botrule Rrule" align="center">0.86 <br>(0.80, 0.93)<sup>b</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">0.94 <br>(0.87, 1.01)<sup>b</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">3.18 <br>(2.49, 4.06)<sup>b</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Omeprazole</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">40 once daily</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">11</td>
                                 <td stylecode="Botrule Rrule" align="center">0.62<br> (0.48, 0.80)</td>
                                 <td stylecode="Botrule Rrule" align="center">0.62<br> (0.51, 0.75) </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Pravastatin</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">10 once daily</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">12</td>
                                 <td stylecode="Botrule Rrule" align="center">1.37<br> (1.11, 1.69)</td>
                                 <td stylecode="Botrule Rrule" align="center"> 1.82 <br>(1.60, 2.08)</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">NA</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Rosuvastatin</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">5 once daily</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">11</td>
                                 <td stylecode="Botrule Rrule" align="center">7.13<br> (5.11, 9.96)</td>
                                 <td stylecode="Botrule Rrule" align="center">2.59<br> (2.09, 3.21) </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">0.59 <br>(0.51, 0.69) </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Rilpivirine</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">25 once daily<br> (morning)<sup>i</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">8</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">2.55<br> (2.08, 3.12)</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top"> 3.25<br> (2.80, 3.77)</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">3.62 <br>(3.12, 4.21)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">Tacrolimus</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">2 single dose</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">12</td>
                                 <td stylecode="Botrule Rrule" align="center">3.99<br> (3.21, 4.97)<sup>c</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">57.13<br> (45.53, 71.69)<sup>c</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">16.56 <br>(12.97, 21.16)<sup>c</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="6" align="left" valign="top">
                                    <ul ultype="ordered" id="l143773291396469674" stylecode="LittleAlpha">
                                       <li>Atazanavir plus 100 mg ritonavir administered in the evening, 12 hours after morning dose of VIEKIRA PAK.</li>
                                       <li>Atazanavir or darunavir or lopinavir parameters are reported.</li>
                                       <li>Dose normalized parameters reported.</li>
                                       <li>30 mg cyclosporine was administered with VIEKIRA PAK in the test arm and 100 mg cyclosporine was administered<content stylecode="bold"></content>in the reference arm without VIEKIRA PAK.</li>
                                       <li>Darunavir administered with VIEKIRA PAK in the morning was compared to darunavir administered with 100 mg ritonavir in the morning.</li>
                                       <li>Darunavir administered with VIEKIRA PAK in the morning and with 100 mg ritonavir in the evening was compared to darunavir administered with 100 mg ritonavir in the morning and evening.</li>
                                       <li>Darunavir plus 100 mg ritonavir administered in the evening, 12 hours after morning dose of VIEKIRA PAK compared to darunavir administered with 100 mg ritonavir in the evening.</li>
                                       <li>Lopinavir/ritonavir administered in the evening, 12 hours after morning dose of VIEKIRA PAK.</li>
                                       <li>Similar increases were observed when rilpivirine was dosed in the evening with food or 4 hours after food.</li>
                                    </ul>
                                    <p id="p4917211291413394324">NA: not available/not applicable; CI: Confidence interval</p>
                                    <p id="p599145291413394341">Doses of ombitasvir, paritaprevir, and ritonavir were 25 mg, 150 mg and 100 mg. Doses of dasabuvir were 250 mg or 400 mg (both doses showed similar exposures).</p>
                                    <p id="p599153291413394353">Ombitasvir, paritaprevir and ritonavir were dosed once daily and dasabuvir was dosed twice daily in all the above studies except studies with ketoconazole and carbamazepine that used single doses.</p>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_12_4" class="safetySubheading">12.4 Microbiology</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p189608291394476892">
                           <content stylecode="underline">Mechanism of Action </content>
                        </p>
                        <p id="p189781291394476918">VIEKIRA PAK combines three direct-acting antiviral agents with distinct mechanisms of action and non-overlapping resistance profiles to target&nbsp;HCV at multiple steps in the viral lifecycle.</p>
                        <p id="p192032291394477130">
                           <content stylecode="italics">Ombitasvir</content>
                        </p>
                        <p id="p192082291394477148">Ombitasvir is an inhibitor of HCV NS5A, which is essential for viral RNA replication and virion assembly. The mechanism of action of ombitasvir has been characterized based on cell culture antiviral activity and drug resistance mapping studies.</p>
                        <p id="p189792291394477095">
                           <content stylecode="italics">Paritaprevir</content>
                        </p>
                        <p id="p184412291409086377">Paritaprevir is an inhibitor of the HCV NS3/4A protease which is necessary for the proteolytic cleavage of the HCV encoded polyprotein (into mature forms of the NS3, NS4A, NS4B, NS5A, and NS5B proteins) and is essential for viral replication. In a biochemical assay, paritaprevir inhibited the proteolytic activity of recombinant HCV genotype 1a and 1b NS3/4A protease enzymes with IC<sub>50</sub> values of 0.18 nM and 0.43 nM, respectively. Paritaprevir inhibited the activity of NS3/4A enzymes from single isolates of genotypes 2a, 2b, 3a, and 4a with IC<sub>50</sub> values of 2.4 nM, 6.3 nM, 14.5 nM, and 0.16 nM, respectively.</p>
                        <p id="p192093291394477167">
                           <content stylecode="italics">Dasabuvir</content>
                        </p>
                        <p id="p435357291409086207">Dasabuvir is a non-nucleoside inhibitor of the HCV RNA-dependent RNA polymerase encoded by the NS5B gene, which is essential for replication of the viral genome. In a biochemical assay, dasabuvir inhibited a panel of genotype 1a and 1b NS5B polymerases with median IC<sub>50 </sub>values of 2.8 nM (range 2.4 nM to 4.2 nM; n = 3) and 3.7 nM (range 2.2 nM to 10.7 nM; n = 4), respectively. Based on drug resistance mapping studies of HCV genotypes 1a and 1b, dasabuvir targets the palm domain of the NS5B polymerase, and is therefore referred to as a non-nucleoside NS5B-palm polymerase inhibitor. Dasabuvir had reduced activity in biochemical assays against NS5B polymerases from HCV genotypes 2a, 2b, 3a and 4a (IC<sub>50</sub> values ranging from 900 nM to &gt;20 μM). </p>
                        <p id="p192213291394477205">
                           <content stylecode="underline">Antiviral Activity</content>
                        </p>
                        <p id="p194582291394477339">
                           <content stylecode="italics">Ombitasvir</content>
                        </p>
                        <p id="p182203291409086467">The EC<sub>50</sub> values of ombitasvir against genotype 1a-H77 and 1b-Con1 strains in HCV replicon cell culture assays were 14.1 pM and 5 pM, respectively. The median EC<sub>50</sub> values of ombitasvir against HCV replicons containing NS5A genes from a panel of genotype 1a and 1b isolates from treatment-naïve subjects were 0.68 pM (range 0.35 to 0.88 pM; n = 11) and 0.94 pM (range 0.74 to 1.5 pM; n = 11), respectively. Ombitasvir had EC<sub>50</sub> values of 12 pM, 4.3 pM, 19 pM, 1.7 pM, 3.2 pM, and 366 pM against chimeric replicons constructed with NS5A from single isolates representing genotypes 2a, 2b, 3a, 4a, 5a, and 6a, respectively.</p>
                        <p id="p192283291394477227">
                           <content stylecode="italics">Paritaprevir</content>
                        </p>
                        <p id="p184633291409086524">The EC<sub>50</sub> values of paritaprevir against genotype 1a-H77 and 1b-Con1 strains in the HCV replicon cell culture assay were 1.0 nM and 0.21 nM, respectively. The median EC<sub>50</sub> values of paritaprevir against HCV replicons containing NS3 genes from a panel of genotype 1a and 1b isolates from treatment-naïve subjects were 0.68 nM (range 0.43 nM to 1.87 nM; n = 11) and 0.06 nM (range 0.03 nM to 0.09 nM; n = 9), respectively. Paritaprevir had an EC<sub>50</sub> value of 5.3 nM against the HCV genotype 2a-JFH-1 replicon cell line, and EC<sub>50</sub> values of 19 nM, 0.09 nM, and 0.68 nM against replicon cell lines containing NS3 from a single isolate each of genotype 3a, 4a, and 6a, respectively.</p>
                        <p id="p186973291409086554">In HCV replicon cell culture assays, ritonavir did not exhibit a direct antiviral effect and the presence of ritonavir did not affect the antiviral activity of paritaprevir.</p>
                        <p id="p194643291394477373">
                           <content stylecode="italics">Dasabuvir</content>
                        </p>
                        <p id="p187043291409086637">The EC<sub>50</sub> values of dasabuvir against genotype 1a-H77 and 1b-Con1 strains in HCV replicon cell culture assays were 7.7 nM and 1.8 nM, respectively. The median EC<sub>50</sub> values of dasabuvir against HCV replicons containing NS5B genes from a panel of genotype 1a and 1b isolates from treatment-naïve subjects were 0.6 nM (range 0.4 nM to 2.1 nM; n = 11) and 0.3 nM (range 0.2 nM to 2 nM; n = 10), respectively.</p>
                        <p id="p158843291395844879">
                           <content stylecode="underline">Combination Antiviral Activity</content>
                        </p>
                        <p id="p187295291409086998">Evaluation of pairwise combinations of ombitasvir, paritaprevir, dasabuvir and ribavirin in HCV genotype 1 replicon cell culture assays showed no evidence of antagonism in antiviral activity. </p>
                        <p id="p197272291394477712">
                           <content stylecode="underline">Resistance</content>
                        </p>
                        <p id="p189493291409087019">
                           <content stylecode="italics">In Cell Culture</content>
                        </p>
                        <p id="p514882291409087687">Exposure of HCV genotype 1a and 1b replicons to ombitasvir, paritaprevir or dasabuvir resulted in the emergence of drug resistant replicons carrying amino acid substitutions in NS5A, NS3, or NS5B, respectively. Amino acid substitutions in NS5A, NS3, or NS5B selected in cell culture or identified in Phase 2b and 3 clinical trials were phenotypically characterized in genotype 1a or 1b replicons.</p>
                        <p id="p514901291409087690">For ombitasvir, in HCV genotype 1a replicons single NS5A substitutions M28T/V, Q30E/R, L31V, H58D, and Y93C/H/L/N reduced ombitasvir antiviral activity by 58- to 67,000-fold. In genotype 1b replicons, single NS5A substitutions L28T, L31F/V, and Y93H reduced ombitasvir antiviral activity by 8- to 661-fold.   In general, combinations of ombitasvir resistance-associated substitutions in HCV genotype 1a or 1b replicons further reduced ombitasvir antiviral activity.</p>
                        <p id="p514921291409087692">For paritaprevir, in HCV genotype 1a replicons single NS3 substitutions F43L, R155G/K/S, A156T, and D168A/E/F/H/N/V/Y reduced paritaprevir antiviral activity by 7- to 219-fold. An NS3 Q80K substitution in a genotype 1a replicon reduced paritaprevir antiviral activity by 3-fold.  Combinations of V36M, Y56H, or E357K with R155K or D168 substitutions reduced the activity of paritaprevir by an additional 2- to 7-fold relative to the single R155K or D168 substitutions in genotype 1a replicons. In genotype 1b replicons single NS3 substitutions A156T and D168A/H/V reduced paritaprevir antiviral activity by 7- to 159-fold. The combination of Y56H with D168 substitutions reduced the activity of paritaprevir by an additional 16- to 26-fold relative to the single D168 substitutions in genotype 1b replicons.</p>
                        <p id="p514941291409087693">For dasabuvir, in HCV genotype 1a replicons single NS5B substitutions C316Y, M414I/T, E446K/Q, Y448C/H, A553T, G554S, S556G/R, and Y561H reduced dasabuvir antiviral activity by 8- to 1,472-fold. In genotype 1b replicons, single NS5B substitutions C316H/N/Y,  S368T, N411S, M414I/T, Y448C/H, A553V, S556G and D559G reduced dasabuvir antiviral activity by 5- to 1,569-fold.</p>
                        <p id="p409662291395849344">
                           <content stylecode="italics">In Clinical Studies</content>
                        </p>
                        <p id="p409721291395849397">In a pooled analysis of subjects treated with regimens containing ombitasvir, paritaprevir, and dasabuvir with or without ribavirin (for 12 or 24 weeks) in Phase 2b and Phase 3 clinical trials, resistance analyses were conducted for 64 subjects who experienced virologic failure (20 with on-treatment virologic failure, 44 with post-treatment relapse). Treatment-emergent substitutions observed in the viral populations of these subjects are shown in <a href="#table_8">Table 8</a>. Treatment-emergent substitutions were detected in all 3 HCV drug targets in 30/57 (53%) HCV genotype 1a infected subjects, and 1/6 (17%) HCV genotype 1b infected subjects.</p>
                        <table id="table_8" frame="box" width="100%">
                           <caption>Table 8. Treatment-Emergent Amino Acid Substitutions in the Pooled Analysis of VIEKIRA PAK with and without Ribavirin Regimens (12- or 24-week durations) in Phase 2b and Phase 3 Clinical Trials</caption>
                           <colgroup>
                              <col width="12%">
                              <col width="58%">
                              <col width="15%">
                              <col width="15%">
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">
                                    <content stylecode="bold">Target</content>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">
                                    <content stylecode="bold">Emergent Amino Acid Substitutions</content>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">
                                    <content stylecode="bold">Genotype 1a</content>
                                    <br>
                                    <content stylecode="bold">N = 58<sup>a</sup>
                                    </content>
                                    <br>
                                    <content stylecode="bold">% (n)</content>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">
                                    <content stylecode="bold">Genotype 1b</content>
                                    <br>
                                    <content stylecode="bold">N = 6</content>
                                    <br>
                                    <content stylecode="bold">% (n)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="15" align="center" valign="top">NS3</td>
                                 <td stylecode="Botrule Rrule" align="center">Any of the following NS3 substitutions: V36A/M/T, F43L, V55I, Y56H, Q80L, I132V, R155K, A156G, D168(any), P334S, S342P, E357K, V406A/I, T449I, P470S, V23A (NS4A)</td>
                                 <td stylecode="Botrule Rrule" align="center">88 (51)</td>
                                 <td stylecode="Botrule Rrule" align="center">67 (4)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">V36A/M/T<sup>b</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">7 (4)</td>
                                 <td stylecode="Botrule" align="center">--</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">V55I<sup>b </sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">7 (4) </td>
                                 <td stylecode="Botrule" align="center">--</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">Y56H<sup>b</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">10 (6) </td>
                                 <td stylecode="Botrule Rrule" align="center">50 (3)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">I132V<sup>b</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">7 (4) </td>
                                 <td stylecode="Botrule" align="center">--</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">R155K</td>
                                 <td stylecode="Botrule Rrule" align="center">16 (9)</td>
                                 <td stylecode="Botrule" align="center">--</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">D168 (any)<sup>d</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">72 (42) </td>
                                 <td stylecode="Botrule Rrule" align="center">67 (4)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">D168V </td>
                                 <td stylecode="Botrule Rrule" align="center">59 (34) </td>
                                 <td stylecode="Botrule Rrule" align="center">50 (3)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">P334S<sup>b,c</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center"> 7 (4)</td>
                                 <td stylecode="Botrule" align="center">--</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">E357K<sup>b,c</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">5 (3)</td>
                                 <td stylecode="Botrule Rrule" align="center">17 (1)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">V406A/I<sup>b,c</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">5 (3)</td>
                                 <td stylecode="Botrule" align="center">--</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">T449I<sup>b,c</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">5 (3)</td>
                                 <td stylecode="Botrule" align="center">--</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">P470S<sup>b,c</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">5 (3)</td>
                                 <td stylecode="Botrule" align="center">--</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">NS4A V23A<sup>b</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">--</td>
                                 <td stylecode="Botrule Rrule" align="center">17 (1)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">F43L<sup>b</sup>, Q80L<sup>b</sup>, A156G, S342P<sup>b,c</sup>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center">&lt;5%</td>
                                 <td stylecode="Botrule" align="center">--</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="8" align="center" valign="top">NS5A</td>
                                 <td stylecode="Botrule Rrule" align="center">Any of the following NS5A substitutions: K24R, M28A/T/V, Q30E/K/R, H/Q54Y, H58D/P/R, Y93C/H/N</td>
                                 <td stylecode="Botrule Rrule" align="center">78 (45)</td>
                                 <td stylecode="Botrule Rrule" align="center">33 (2)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">K24R </td>
                                 <td stylecode="Botrule Rrule" align="center">5 (3) </td>
                                 <td stylecode="Botrule" align="center">--</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">M28A/T/V </td>
                                 <td stylecode="Botrule Rrule" align="center">33 (19) </td>
                                 <td stylecode="Botrule" align="center">--</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">Q30E/K/R </td>
                                 <td stylecode="Botrule Rrule" align="center">47 (27) </td>
                                 <td stylecode="Botrule" align="center">--</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">H/Q54Y</td>
                                 <td stylecode="Botrule Rrule" align="center">--</td>
                                 <td stylecode="Botrule Rrule" align="center">17(1)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">H58D/P/R</td>
                                 <td stylecode="Botrule Rrule" align="center">7 (4)</td>
                                 <td stylecode="Botrule" align="center">--</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">Y93C/N </td>
                                 <td stylecode="Botrule Rrule" align="center">&nbsp;5 (3)</td>
                                 <td stylecode="Botrule" align="center">--</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">Y93H</td>
                                 <td stylecode="Botrule Rrule" align="center">--</td>
                                 <td stylecode="Botrule Rrule" align="center">33 (2)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" rowspan="9" align="center" valign="top">NS5B</td>
                                 <td stylecode="Botrule Rrule" align="center">Any of the following NS5B substitutions: G307R, C316Y, M414I/T, E446K/Q, A450V, A553I/T/V, G554S, S556G/R, G558R, D559G/I/N/V, Y561H</td>
                                 <td stylecode="Botrule Rrule" align="center">67 (38)</td>
                                 <td stylecode="Botrule Rrule" align="center">33 (2)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">C316Y</td>
                                 <td stylecode="Botrule Rrule" align="center">4 (2)</td>
                                 <td stylecode="Botrule Rrule" align="center">17 (1)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">M414I</td>
                                 <td stylecode="Botrule Rrule" align="center">--</td>
                                 <td stylecode="Botrule Rrule" align="center">17 (1)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">M414T</td>
                                 <td stylecode="Botrule Rrule" align="center">5 (3)</td>
                                 <td stylecode="Botrule Rrule" align="center">17 (1)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">A553I/T/V</td>
                                 <td stylecode="Botrule Rrule" align="center">7 (4) </td>
                                 <td stylecode="Botrule" align="center">--</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">S556G/R </td>
                                 <td stylecode="Botrule Rrule" align="center">39 (22) </td>
                                 <td stylecode="Botrule Rrule" align="center">17 (1)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">D559G/I/N/V</td>
                                 <td stylecode="Botrule Rrule" align="center">7 (4)</td>
                                 <td stylecode="Botrule" align="center">--</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">Y561H</td>
                                 <td stylecode="Botrule Rrule" align="center">5 (3)</td>
                                 <td stylecode="Botrule" align="center">--</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="center">G307R,  E446K/Q, A450V, G554S,  G558R</td>
                                 <td stylecode="Botrule Rrule" align="center">&lt;5%</td>
                                 <td stylecode="Botrule" align="center">--</td>
                              </tr>
                              <tr>
                                 <td colspan="4" align="left" valign="top">
                                    <ul ultype="ordered" id="l4841110291396469733" stylecode="LittleAlpha">
                                       <li>N = 57 for the NS5B target.</li>
                                       <li>Substitutions were observed in combination with other emergent substitutions at NS3 position R155 or D168.</li>
                                       <li>Position located in NS3 helicase domain.</li>
                                       <li>D168A/F/H/I/L/N/T/V/Y.</li>
                                    </ul>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <p id="p199851291394478125">
                           <content stylecode="underline">Persistence of Resistance-Associated Substitutions</content>
                        </p>
                        <p id="p4405542551409088565">The persistence of ombitasvir, paritaprevir, and dasabuvir treatment-emergent amino acid substitutions in NS5A, NS3, and NS5B, respectively, was assessed in HCV genotype 1a-infected subjects in Phase 2 trials whose virus had at least 1 treatment-emergent resistance-associated substitution in the drug target, and with available data through at least 24 weeks post-treatment.  Population and clonal nucleotide sequence analyses (assay sensitivity approximately 5-10%) were conducted to detect the persistence of viral populations with treatment-emergent substitutions.</p>
                        <p id="p5147762551409088576">For ombitasvir, viral populations with 1 or more resistance-associated treatment-emergent substitutions in NS5A persisted at detectable levels through at least Post-Treatment Week 24 in 24/24 (100%) subjects, and through Post-Treatment Week 48 in 18/18 (100%) subjects with available data.</p>
                        <p id="p5147912551409088579">For paritaprevir, viral populations with 1 or more treatment-emergent substitutions in NS3 persisted at detectable levels through at least Post-Treatment Week 24 in 17/29 (59%) subjects, and through Post-Treatment Week 48 in 5/22 (23%) subjects with available data.  Resistance-associated variant R155K remained detectable in 5/8 (63%) subjects through Post-Treatment Week 24, and in 1/5 (20%) subjects through Post-Treatment Week 48. Resistance-associated D168 substitutions remained detectable in 6/22 (27%) subjects through Post-Treatment Week 24, and were no longer detectable through Post-Treatment Week 48. </p>
                        <p id="p5148112551409088582">For dasabuvir, viral populations with 1 or more treatment-emergent substitutions in NS5B persisted at detectable levels through at least Post-Treatment Week 24 in 11/16 (69%) subjects, and through Post-Treatment Week 48 in 8/15 (53%) subjects with available data.  Treatment-emergent S556G persisted through Post-Treatment Week 48 in 6/9 (67%) subjects.</p>
                        <p id="p5148312551409088583">Due to virologic failure rates in clinical trials of less than 1% for subjects infected with HCV genotype 1b, trends in persistence of treatment-emergent substitutions in this genotype could not be established.</p>
                        <p id="p5148512551409088585">The lack of detection of virus containing a resistance-associated substitution does not indicate that the resistant virus is no longer present at clinically significant levels. The long-term clinical impact of the emergence or persistence of virus containing VIEKIRA PAK-resistance-associated substitutions is unknown.</p>
                        <p id="p5148712551409088586">
                           <content stylecode="underline">Effect of Baseline HCV Polymorphisms on Treatment Response</content>
                        </p>
                        <p id="p5148912551409088588">A pooled analysis of subjects in the Phase 3 clinical trials of ombitasvir, paritaprevir, and dasabuvir with or without ribavirin was conducted to explore the association between baseline HCV NS5A, NS3, or NS5B resistance-associated polymorphisms and treatment outcome. Baseline samples from HCV genotype 1a infected subjects who experienced virologic failure (n=47), as well as samples from a subset of demographically matched subjects who achieved SVR (n=94), were analyzed to compare the frequencies of resistance-associated polymorphisms in these two populations. The NS3 Q80K polymorphism was detected in approximately 38% of subjects in this analysis and was enriched approximately 2-fold in virologic failure subjects compared to SVR-achieving subjects.  Ombitasvir resistance-associated polymorphisms in NS5A (pooling data from all resistance-associated amino acid positions) were detected in approximately 22% of subjects in this analysis and similarly were enriched approximately 2-fold in virologic failure subjects.  Dasabuvir resistance-associated polymorphisms in NS5B were detected in approximately 5% of subjects in this analysis and were not enriched in virologic failure subjects.</p>
                        <p id="p4354110291412969171">In contrast to the Phase 3 subset analysis, no association of NS3 or NS5A polymorphisms and treatment outcome was seen in an analysis of noncirrhotic HCV genotype 1a-infected subjects (n=174 for NS3 and n=183 for NS5A) who received ombitasvir, paritaprevir, and dasabuvir with or without ribavirin (for 12 or 24 weeks) in a Phase 2b trial. </p>
                        <p id="p5149112551409088589">Baseline HCV polymorphisms are not expected to have a substantial impact on the likelihood of achieving SVR when VIEKIRA PAK is used as recommended for HCV genotype 1a and 1b infected patients, based on the low virologic failure rates observed in clinical trials.</p>
                        <p id="p199912291394478154">
                           <content stylecode="underline">Cross-resistance</content>
                        </p>
                        <p id="p200023291394478269">Cross-resistance is expected among NS5A inhibitors, NS3/4A protease inhibitors, and non-nucleoside NS5B-palm inhibitors by class. Dasabuvir retained full activity against HCV replicons containing a single NS5B L159F, S282T, or V321A substitution, which are associated with resistance or prior exposure to nucleos(t)ide analogue NS5B polymerase inhibitors. In clinical trials of VIEKIRA PAK, no subjects who experienced virologic failure had treatment-emergent substitutions potentially associated with resistance to nucleot(s)ide analogue NS5B polymerase inhibitors.</p>
                        <p id="p5150432551409088772"> The impact of prior ombitasvir, paritaprevir, or dasabuvir treatment experience on the efficacy of other NS5A inhibitors, NS3/4A protease inhibitors, or NS5B inhibitors has not been studied. Similarly, the efficacy of VIEKIRA PAK has not been studied in subjects who have failed prior treatment with another NS5A inhibitor, NS3/4A protease inhibitor, or NS5B inhibitor.</p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_43680-8">
<div class="drugSubheadings">
<span id="VIEKIRA_PAK_43680-8" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>13 NONCLINICAL TOXICOLOGY</div>
<div id="VIEKIRA_PAK_previewText_43680-8" class="previewText"><span>...</span></div>
</div>
<div id="VIEKIRA_PAK_collapsableElement_43680-8" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"></div>
<span id="VIEKIRA_PAK_collapsableElement_13_1" class="safetySubheading">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</span><div id="34083-6" class="safetySubdescription"><text>
                        <p id="P30">
                           <content stylecode="underline">Carcinogenesis and Mutagenesis</content>
                        </p>
                        <p id="p420294291396365469">
                           <content stylecode="italics">Ombitasvir</content>
                        </p>
                        <p id="p204822291394479272">Ombitasvir was not carcinogenic in a 6-month transgenic mouse study up to the highest dose tested (150 mg per kg per day). Similarly, ombitasvir was not carcinogenic in a 2-year rat study up to the highest dose tested (30 mg per kg per day), resulting in ombitasvir exposures approximately 16-fold higher than those in humans at 25 mg. </p>
                        <p id="p422663291395857596">Ombitasvir and its major inactive human metabolites (M29, M36) were not genotoxic in a battery of <content stylecode="italics">in vitro</content> or <content stylecode="italics">in vivo</content> assays, including bacterial mutagenicity, chromosome aberration using human peripheral blood lymphocytes and <content stylecode="italics">in vivo</content> mouse micronucleus assays.</p>
                        <p id="p200076291394478621">
                           <content stylecode="italics">Paritaprevir, ritonavir</content>
                        </p>
                        <p id="p179593291395857492">Paritaprevir, ritonavir was not carcinogenic in a 6-month transgenic mouse study up to the highest dose tested (300/30 mg per kg per day). Similarly, paritaprevir, ritonavir was not carcinogenic in a 2-year rat study up to the highest dose tested (300/30 mg per kg per day), resulting in paritaprevir exposures approximately 9-fold higher than those in humans at 150 mg.</p>
                        <p id="p179584291395857514">Paritaprevir was positive in an <content stylecode="italics">in vitro</content> chromosome aberration test using human lymphocytes. Paritaprevir was negative in a bacterial mutation assay, and in two <content stylecode="italics">in vivo</content> genetic toxicology assays (rat bone marrow micronucleus and rat liver Comet tests).</p>
                        <p id="p202432291394478888">
                           <content stylecode="italics">Dasabuvir</content>
                        </p>
                        <p id="p202501291394478918">Dasabuvir was not carcinogenic in a 6-month transgenic mouse study up to the highest dose tested (2000 mg per kg per day). Similarly, dasabuvir was not carcinogenic in a 2-year rat study up to the highest dose tested (800 mg per kg per day), resulting in dasabuvir exposures approximately 19-fold higher than those in humans at 500 mg.</p>
                        <p id="p202542291394478945">Dasabuvir was not genotoxic in a battery of <content stylecode="italics">in vitro </content>or <content stylecode="italics">in vivo </content>assays, including bacterial mutagenicity, chromosome aberration using human peripheral blood lymphocytes and <content stylecode="italics">in vivo </content>rat micronucleus assays.</p>
                        <p id="p519942291413211720">If VIEKIRA PAK is administered with ribavirin, refer to the prescribing information for ribavirin for information on carcinogenesis, and mutagenesis.</p>
                        <p id="p202572291394479102">
                           <content stylecode="underline">Impairment of Fertility</content>
                        </p>
                        <p id="p205002291394479451">
                           <content stylecode="italics">Ombitasvir</content>
                        </p>
                        <p id="p205052291394479463">Ombitasvir had no effects on embryo-fetal viability or on fertility when evaluated in mice up to the highest dose of 200 mg per kg per day. Ombitasvir exposures at this dose were approximately 25-fold the exposure in humans at the recommended clinical dose.</p>
                        <p id="p204922291394479371">
                           <content stylecode="italics">Paritaprevir, ritonavir </content>
                        </p>
                        <p id="p204972291394479429">Paritaprevir, ritonavir had no effects on embryo-fetal viability or on fertility when evaluated in rats up to the highest dose of 300/30 mg per kg per day. Paritaprevir exposures at this dose were approximately 2- to 5-fold the exposure in humans at the recommended clinical dose.</p>
                        <p id="p205063291394479489">
                           <content stylecode="italics">Dasabuvir</content>
                        </p>
                        <p id="p205132291394479500">Dasabuvir had no effects on embryo-fetal viability or on fertility when evaluated in rats up to the highest dose of 800 mg per kg per day. Dasabuvir exposures at this dose were approximately 16-fold the exposure in humans at the recommended clinical dose.</p>
                        <p id="p519686291413211952">If VIEKIRA PAK is administered with ribavirin, refer to the prescribing information for ribavirin for information on Impairment of Fertility.</p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34092-7">
<div class="drugSubheadings">
<span id="VIEKIRA_PAK_34092-7" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>14 CLINICAL STUDIES</div>
<div id="VIEKIRA_PAK_previewText_34092-7" class="previewText"><span>...</span></div>
</div>
<div id="VIEKIRA_PAK_collapsableElement_34092-7" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"></div>
<span id="VIEKIRA_PAK_collapsableElement_14_1" class="safetySubheading">14.1 Description of Clinical Trials </span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p4249814291395858638">The efficacy and safety of VIEKIRA PAK was evaluated in six randomized, multicenter, clinical trials in 2,308 subjects with genotype 1 (GT1) chronic hepatitis C  virus (HCV) infection, including one trial exclusively in subjects with cirrhosis with mild hepatic impairment (Child-Pugh A), as summarized in <a href="#table_9">Table 9</a>.</p>
                        <table id="table_9" frame="box" width="100%">
                           <caption>Table 9. Randomized, Multicenter Trials Conducted with VIEKIRA PAK With or Without Ribavirin (RBV) in Subjects with Chronic HCV GT1 Infection</caption>
                           <colgroup>
                              <col width="25%">
                              <col width="24%">
                              <col width="49%">
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td stylecode="Botrule Rrule" valign="top">
                                    <content stylecode="bold">Trial</content>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">
                                    <content stylecode="bold">Population</content>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">
                                    <content stylecode="bold">Study Arms</content>
                                    <br>
                                    <content stylecode="bold">(Number of Subjects Treated)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule">SAPPHIRE-I<br>(double-blind)</td>
                                 <td stylecode="Botrule Rrule" align="center">GT1 (a and b) <br>TN<sup>a</sup> without cirrhosis</td>
                                 <td stylecode="Botrule Rrule" align="left">
                                    <ul ultype="unordered" id="l460887291415803676" stylecode="Disc">
                                       <li>VIEKIRA PAK + RBV (473)</li>
                                       <li>Placebo (158)</li>
                                    </ul>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule">SAPPHIRE-II<br>(double-blind)</td>
                                 <td stylecode="Botrule Rrule" align="center">GT1 (a and b) <br>TE<sup>b</sup> without cirrhosis</td>
                                 <td stylecode="Botrule Rrule" align="left" valign="top">
                                    <ul ultype="unordered" id="l450990291415803727" stylecode="Disc">
                                       <li>VIEKIRA PAK + RBV (297)</li>
                                       <li>Placebo (97)</li>
                                    </ul>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule">PEARL-II<br>(open-label) </td>
                                 <td stylecode="Botrule Rrule" align="center">GT1b<br>TE without cirrhosis</td>
                                 <td stylecode="Botrule Rrule" align="left">
                                    <ul ultype="unordered" id="l453342291415803751" stylecode="Disc">
                                       <li>VIEKIRA PAK + RBV (88) </li>
                                       <li>VIEKIRA PAK  (91)</li>
                                    </ul>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule">PEARL-III<br>(double-blind)  </td>
                                 <td stylecode="Botrule Rrule" align="center">GT1b<br>TN without cirrhosis</td>
                                 <td stylecode="Botrule Rrule" align="left" valign="top">
                                    <ul ultype="unordered" id="l430404291415803789" stylecode="Disc">
                                       <li>VIEKIRA PAK + RBV (210) </li>
                                       <li>VIEKIRA PAK   (209)</li>
                                    </ul>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule">PEARL-IV<br>(double-blind)  </td>
                                 <td stylecode="Botrule Rrule" align="center">GT1a<br>TN without cirrhosis</td>
                                 <td stylecode="Botrule Rrule" align="left" valign="top">
                                    <ul ultype="unordered" id="l430575291415803821" stylecode="Disc">
                                       <li>VIEKIRA PAK + RBV (100) </li>
                                       <li>VIEKIRA PAK  (205)</li>
                                    </ul>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule">TURQUOISE-II<br>(open-label) </td>
                                 <td stylecode="Botrule Rrule" align="center">GT1 (a and b) <br>TN &amp; TE with cirrhosis</td>
                                 <td stylecode="Botrule Rrule" align="left" valign="top">
                                    <ul ultype="unordered" id="l433087291415803853" stylecode="Disc">
                                       <li>VIEKIRA PAK + RBV (12 weeks) (208)</li>
                                       <li>VIEKIRA PAK + RBV (24 weeks) (172)</li>
                                    </ul>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left">
                                    <ul ultype="ordered" id="l4764233421396022759" stylecode="LittleAlpha">
                                       <li>TN, treatment-naïve was defined as not having received any prior therapy for HCV infection.</li>
                                       <li>TE, treatment-experienced subjects were defined as either: prior relapsers, prior partial responders, or prior null responders to pegIFN/RBV treatment.</li>
                                    </ul>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <ul ultype="unordered" id="l433138291415803941" stylecode="Disc">
                           <li>In SAPPHIRE-I and -II, subjects without cirrhosis were randomized to VIEKIRA PAK in combination with ribavirin for 12 weeks or to placebo. Subjects in the placebo arm received placebo for 12 weeks, after which they received open-label VIEKIRA PAK in combination with RBV for 12 weeks <content stylecode="italics">[see Clinical Studies (<a href="#section_14.2">14.2</a>)]</content>.</li>
                           <li>In PEARL-II, -III and -IV, subjects without cirrhosis were randomized to receive VIEKIRA PAK with or without RBV for 12 weeks of treatment<content stylecode="italics"> [see Clinical Studies (<a href="#section_14.2">14.2</a>)]</content>. </li>
                           <li>In the open-label TURQUOISE-II trial, subjects with compensated cirrhosis (Child-Pugh A) who were either treatment-naïve or pegylated interferon/RBV (pegIFN/RBV) treatment-experienced were randomized to receive VIEKIRA PAK in combination with RBV for either 12 or 24 weeks of treatment. Subjects who previously failed therapy with a treatment regimen that included VIEKIRA PAK or other direct-acting antiviral agents were excluded <content stylecode="italics">[see Clinical Studies (<a href="#section_14.3">14.3</a>)]</content>.</li>
                        </ul>
                        <p id="p92523291415804245">In these six clinical trials, the ombitasvir, paritaprevir, ritonavir dose was 25/150/100 mg once daily and the dasabuvir dose was 250 mg twice daily. Doses of drugs in VIEKIRA PAK were not adjusted. For subjects who received RBV, the RBV dose was 1000 mg per day for subjects weighing less than 75 kg or 1200 mg per day for subjects weighing greater than or equal to 75 kg. RBV dose adjustments were performed according to the RBV labeling.</p>
                        <p id="p92534291415804304">VIEKIRA PAK with RBV was also evaluated in the following two studies:</p>
                        <ul ultype="unordered" id="l92603291415804365" stylecode="Disc">
                           <li>HCV GT1-infected liver transplant recipients (CORAL-I) <content stylecode="italics">[see Clinical Studies (<a href="#section_14.5">14.5</a>)]</content>.</li>
                           <li>Subjects with HCV GT1 co-infected with HIV-1 (TURQUOISE-I) <content stylecode="italics">[see Clinical Studies (<a href="#section_14.6">14.6</a>)]</content>.</li>
                        </ul>
                        <p id="p507301291415804763">In all eight clinical studies, sustained virologic response was defined as HCV RNA below the lower limit of quantification (&lt;LLOQ) 12 weeks after the end of treatment (SVR12). Plasma HCV RNA levels were measured using the COBAS TaqMan HCV test (version 2.0), for use with the High Pure System, which has an LLOQ of 25 IU per mL. Outcomes for subjects not achieving an SVR12 were recorded as on-treatment virologic failure (VF), post-treatment virologic relapse through post-treatment Week 12 or failure due to other non-virologic reasons (e.g., premature discontinuation, adverse event, lost to follow-up, consent withdrawn).</p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_14_2" class="safetySubheading">14.2 Clinical Trial Results in Adults with Chronic HCV Genotype 1a and 1b Infection without Cirrhosis
                     </span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p2155214291394480605">
                           <content stylecode="underline">Subjects with Chronic HCV GT1a Infection without Cirrhosis</content>
                        </p>
                        <p id="p217703291394480637">Subjects with HCV GT1a infection without cirrhosis treated with VIEKIRA PAK with RBV for 12 weeks in SAPPHIRE-I and -II and in PEARL-IV <content stylecode="italics">[see Clinical Studies (<a href="#section_14.1">14.1</a>)]</content> had a median age of 53 years (range: 18 to 70); 63% of the subjects were male; 90% were White; 7% were Black/African American; 8% were Hispanic or Latino; 19% had a body mass index of at least 30 kg per m<sup>2</sup>; 55% of patients were enrolled in US sites; 72% had IL28B (rs12979860) non-CC genotype; 85% had baseline HCV RNA levels of at least 800,000 IU per mL.</p>
                        <p id="p217677291394480653">
                           <a href="#table_10">Table 10</a> presents treatment outcomes for HCV GT1a treatment-naïve and treatment-experienced subjects treated with VIEKIRA PAK with RBV for 12 weeks in SAPPHIRE-I, PEARL-IV and SAPPHIRE-II.</p>
                        <p id="p509551291415805030">Treatment-naïve, HCV GT1a-infected subjects without cirrhosis treated with VIEKIRA PAK in combination with RBV for 12 weeks in PEARL-IV had a significantly higher SVR12 rate than subjects treated with VIEKIRA PAK alone (97% and 90% respectively; difference +7%  with 95% confidence interval, +1% to +12%). VIEKIRA PAK alone was not studied in treatment-experienced subjects with GT1a infection.</p>
                        <p id="p509581291415805104">In SAPPHIRE-I and SAPPHIRE-II, no placebo subject achieved a HCV RNA &lt;25 IU/mL during treatment.  </p>
                        <table id="table_10" frame="box" width="75%">
                           <caption>Table 10. SVR12 for HCV Genotype 1a-Infected Subjects without Cirrhosis Who Were Treatment-Naïve or Previously Treated with PegIFN/RBV</caption>
                           <colgroup>
                              <col width="60%">
                              <col width="40%">
                           </colgroup>
                           <thead>
                              <tr>
                                 <th stylecode="Botrule Rrule" align="center" valign="middle">&nbsp;</th>
                                 <th stylecode="Botrule" align="center" valign="top">
                                    <content stylecode="bold">VIEKIRA PAK with RBV</content>
                                    <br>
                                    <content stylecode="bold">for 12&nbsp;Weeks</content>
                                    <br>
                                    <content stylecode="bold">% (n/N)</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td stylecode="Botrule" colspan="2">
                                    <content stylecode="bold">GT1a treatment-naïve</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">
                                    <content stylecode="bold">SAPPHIRE-I SVR12</content>
                                 </td>
                                 <td align="center" valign="top">96% (308/322)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">Outcome for subjects without SVR12</td>
                                 <td align="center" valign="top">&nbsp;</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">&nbsp;&nbsp;On-treatment VF</td>
                                 <td align="center" valign="top">&lt;1% (1/322)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">&nbsp;&nbsp;Relapse</td>
                                 <td align="center" valign="top">2% (6/314)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="left" valign="top">&nbsp;&nbsp;Other </td>
                                 <td stylecode="Botrule" align="center" valign="top">2% (7/322)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">
                                    <content stylecode="bold">PEARL-IV SVR12</content>
                                 </td>
                                 <td align="center" valign="top">97% (97/100)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">Outcome for subjects without SVR12</td>
                                 <td align="center" valign="top">&nbsp;</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">&nbsp;&nbsp;On-treatment VF</td>
                                 <td align="center" valign="top">1% (1/100)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">&nbsp;&nbsp;Relapse</td>
                                 <td align="center" valign="top">1% (1/98)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="left" valign="top">&nbsp;&nbsp;Other </td>
                                 <td stylecode="Botrule" align="center" valign="top">1% (1/100)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule" colspan="2" align="left" valign="top">
                                    <content stylecode="bold">GT1a treatment-experienced </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">
                                    <content stylecode="bold">SAPPHIRE-II SVR12</content>
                                 </td>
                                 <td align="center" valign="top">96% (166/173)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">Outcome for subjects without SVR12</td>
                                 <td align="center" valign="top">&nbsp;</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">&nbsp;&nbsp;On-treatment VF</td>
                                 <td align="center" valign="top">0% (0/173)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">&nbsp;&nbsp;Relapse</td>
                                 <td align="center" valign="top">3% (5/172)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="left" valign="top">&nbsp;&nbsp;Other </td>
                                 <td stylecode="Botrule" align="center" valign="top">1% (2/173)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">
                                    <content stylecode="bold">SVR12 by Prior pegIFN Experience</content>
                                 </td>
                                 <td align="center" valign="top">&nbsp;</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">&nbsp;&nbsp;Null Responder</td>
                                 <td align="center" valign="top">95% (83/87)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">&nbsp;&nbsp;Partial Responder</td>
                                 <td align="center" valign="top">100% (36/36)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">&nbsp;&nbsp;Relapser</td>
                                 <td align="center" valign="top">94% (47/50)</td>
                              </tr>
                           </tbody>
                        </table>
                        <p id="p228216291394481929">
                           <content stylecode="underline">Subjects with Chronic HCV GT1b Infection without Cirrhosis</content>
                        </p>
                        <p id="p228337291394481948">Subjects with HCV GT1b infection without cirrhosis were treated with VIEKIRA PAK with or without RBV for 12 weeks in PEARL-II and -III <content stylecode="italics">[see Clinical Studies (<a href="#section_14.1">14.1</a>)]</content>. Subjects had a median age of 52 years (range: 22 to 70); 47% of the subjects were male; 93% were White; 5% were Black/African American; 2% were Hispanic or Latino; 21% had a body mass index of at least 30 kg per m<sup>2</sup>; 21% of patients were enrolled in US sites; 83% had IL28B (rs12979860) non-CC genotype; 77% had baseline HCV RNA levels of at least 800,000 IU per mL.</p>
                        <p id="p4637972321417656672">The SVR rate for HCV GT1b-infected subjects without cirrhosis treated with VIEKIRA PAK without RBV for 12 weeks in PEARL-II (treatment-experienced: null responder, n=32; partial responder, n=26; relapser, n=33) and PEARL-III (treatment-naïve, n=209) was 100%.</p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_14_3" class="safetySubheading">14.3 Clinical Trial Results in Adults with Chronic HCV Genotype 1a and 1b Infection and Compensated Cirrhosis</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p343253291413398935">TURQUOISE-II was an open-label trial that enrolled 380 HCV GT1a and 1b-infected subjects with cirrhosis and mild hepatic impairment (Child-Pugh A) who were either treatment-naïve or did not achieve SVR with prior treatment with pegIFN/RBV. Subjects were randomized to receive VIEKIRA PAK in combination with RBV for either 12 or 24 weeks of treatment.</p>
                        <p id="p343233291413398939">Treated subjects  had a median age of 58 years (range: 21 to 71); 70% of the subjects were male; 95% were White; 3% were Black/African American; 12% were Hispanic or Latino; 28% had a body mass index of at least 30 kg per m<sup>2</sup>; 43% of patients were enrolled in US sites; 82% had IL28B (rs12979860) non‑CC genotype; 86% had baseline HCV RNA levels of at least 800,000 IU per mL; 69% had HCV GT1a infection, 31% had HCV GT1b infection; 42% were treatment-naïve, 36% were prior pegIFN/RBV null responders; 8% were prior pegIFN/RBV partial responders, 14% were prior pegIFN/RBV relapsers; 15% had platelet counts of less than 90 x 10<sup>9</sup> per L; 50% had albumin less than 4.0 mg per dL.</p>
                        <p id="p343215291413398977">
                           <a href="#table_11">Table 11</a> presents treatment outcomes for GT1 treatment-naïve and treatment-experienced subjects with cirrhosis treated with VIEKIRA PAK with RBV for 12 or 24 weeks in TURQUOISE-II. In GT1a infected subjects, the overall SVR12 rate difference between 24 and 12 weeks of treatment with VIEKIRA PAK with RBV was +6% with 95% confidence interval, -0.1% to +13% with differences varying by pretreatment history.</p>
                        <table id="table_11" frame="box" rules="all" width="100%">
                           <caption>Table 11. TURQUOISE-II: SVR12 for Chronic HCV Genotype 1-Infected Subjects with Cirrhosis Who Were Treatment-Naïve or Previously Treated with pegIFN/RBV</caption>
                           <colgroup>
                              <col>
                              <col span="3">
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td stylecode="Rrule" valign="top">&nbsp;</td>
                                 <td stylecode="Lrule  Botrule Rrule" colspan="2" align="center" valign="top">
                                    <content stylecode="bold">GT1a</content>
                                 </td>
                                 <td stylecode="Botrule" align="center" valign="top">
                                    <content stylecode="bold">GT1b</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="center" valign="top">&nbsp;</td>
                                 <td stylecode="Lrule Botrule Rrule" align="center" valign="top">
                                    <content stylecode="bold">VIEKIRA PAK</content>
                                    <br>
                                    <content stylecode="bold">with RBV for</content>
                                    <br>
                                    <content stylecode="bold">24&nbsp;Weeks</content>
                                    <br>
                                    <content stylecode="bold">% (n/N)</content>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">
                                    <content stylecode="bold">VIEKIRA PAK</content>
                                    <br>
                                    <content stylecode="bold">with RBV for</content>
                                    <br>
                                    <content stylecode="bold">12&nbsp;Weeks</content>
                                    <br>
                                    <content stylecode="bold">% (n/N)</content>
                                 </td>
                                 <td align="center" valign="top">
                                    <content stylecode="bold">VIEKIRA PAK</content>
                                    <br>
                                    <content stylecode="bold">with RBV for</content>
                                    <br>
                                    <content stylecode="bold">12&nbsp;Weeks</content>
                                    <br>
                                    <content stylecode="bold">% (n/N)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">
                                    <content stylecode="bold">SVR12</content>
                                 </td>
                                 <td stylecode="Rrule" align="center" valign="top">95% (115/121)</td>
                                 <td stylecode="Rrule" align="center" valign="top">89% (124/140)</td>
                                 <td align="center" valign="top">99% (67/68)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">
                                    <content stylecode="bold">Outcome for subjects without SVR12</content>
                                 </td>
                                 <td stylecode="Rrule" align="center" valign="top">&nbsp;</td>
                                 <td stylecode="Rrule" align="center" valign="top">&nbsp;</td>
                                 <td align="center" valign="top">&nbsp;</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;On-treatment VF</td>
                                 <td stylecode="Rrule" align="center" valign="top">2% (3/121)</td>
                                 <td stylecode="Rrule" align="center" valign="top">&lt;1% (1/140)</td>
                                 <td align="center" valign="top">0% (0/68)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;Relapse</td>
                                 <td stylecode="Rrule" align="center" valign="top">1% (1/116)</td>
                                 <td stylecode="Rrule" align="center" valign="top">8% (11/135)</td>
                                 <td align="center" valign="top">1% (1/68)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;Other </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">2% (2/121)</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">3% (4/140)</td>
                                 <td stylecode="Botrule" align="center" valign="top">0% (0/68)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule Rrule" align="left" valign="top">
                                    <content stylecode="bold">SVR12 for Naïve</content>
                                 </td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">95% (53/56)</td>
                                 <td stylecode="Botrule Rrule" align="center" valign="top">92% (59/64)</td>
                                 <td stylecode="Botrule" align="center" valign="top">100% (22/22)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">
                                    <content stylecode="bold">SVR12 by Prior pegIFN Experience</content>
                                 </td>
                                 <td stylecode="Rrule" align="center" valign="top">&nbsp;</td>
                                 <td stylecode="Rrule" align="center" valign="top">&nbsp;</td>
                                 <td align="center" valign="top">&nbsp;</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;Null Responder</td>
                                 <td stylecode="Rrule" align="center" valign="top">93% (39/42)</td>
                                 <td stylecode="Rrule" align="center" valign="top">80% (40/50)</td>
                                 <td align="center" valign="top">100% (25/25)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;Partial Responder</td>
                                 <td stylecode="Rrule" align="center" valign="top">100% (10/10)</td>
                                 <td stylecode="Rrule" align="center" valign="top">100% (11/11)</td>
                                 <td align="center" valign="top">86% (6/7)</td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule" align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;Relapser </td>
                                 <td stylecode="Rrule" align="center" valign="top">100% (13/13)</td>
                                 <td stylecode="Rrule" align="center" valign="top">93% (14/15)</td>
                                 <td align="center" valign="top">100% (14/14)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_14_4" class="safetySubheading">14.4  Effect of Ribavirin Dose Reductions on SVR12</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p455742291415806140">Seven percent of subjects (101/1551) treated with VIEKIRA PAK with RBV had a RBV dose adjustment due to a decrease in hemoglobin level; of these, 98% (98/100) achieved an SVR12. </p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_14_5" class="safetySubheading">14.5 Clinical Trial of Selected Liver Transplant Recipients (CORAL-I)</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p4966715291415806195">VIEKIRA PAK with RBV was administered for 24 weeks to 34 HCV GT1-infected liver transplant recipients who were at least 12 months post transplantation at enrollment with normal hepatic function and mild fibrosis (Metavir fibrosis score F2 or lower). The initial dose of RBV was left to the discretion of the investigator with 600 to 800 mg per day being the most frequently selected dose range at initiation of VIEKIRA PAK and at the end of treatment.</p>
                        <p id="p335717291415806201">Of the 34 subjects (29 with HCV GT1a infection and 5 with HCV GT1b infection) enrolled, (97%) achieved SVR12 (97% in subjects with GT1a infection and 100% of subjects with GT1b infection). One subject with HCV GT1a infection relapsed post-treatment.</p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_14_6" class="safetySubheading">14.6 Clinical Trial in Subjects with HCV/HIV-1 Co-infection (TURQUOISE-I)</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p335834291415806264">In an open-label clinical trial 63 subjects with HCV GT1 infection co-infected with HIV-1 were treated for 12 or 24 weeks with VIEKIRA PAK in combination with RBV. Subjects were on a stable HIV-1 antiretroviral therapy (ART) regimen that included tenofovir disoproxil fumarate plus emtricitabine or lamivudine, administered with ritonavir boosted atazanavir or raltegravir.  Subjects on atazanavir stopped the ritonavir component of their HIV-1 ART regimen upon initiating treatment with VIEKIRA PAK in combination with RBV.&nbsp; Atazanavir was taken with the morning dose of VIEKIRA PAK. The ritonavir component of the HIV-1 ART regimen was restarted after completion of treatment with VIEKIRA PAK and RBV.</p>
                        <p id="p332956291415806271">Treated&nbsp;subjects had a median age of 51 years (range: 31 to 69); 24% of subjects were black; 81% of subjects had IL28B (rs12979860) non-CC genotype; 19% of subjects had compensated cirrhosis; 67% of subjects were HCV treatment-naïve; 33% of subjects had failed prior treatment with pegIFN/RBV; 89% of subjects had HCV genotype 1a infection.</p>
                        <p id="p332934291415806285">The SVR12 rates were 91% (51/56) for subjects with HCV GT1a infection and 100% (7/7) for those with HCV GT1b infection.  Of the 5 subjects who were non-responders, 1 experienced virologic breakthrough, 1 discontinued treatment, 1 experienced relapse and 2 subjects had evidence of HCV re-infection post-treatment.</p>
                        <p id="p332904291415806309">One subject had confirmed HIV-1 RNA &gt;400 copies/mL during the post-treatment period. This subject had no evidence of resistance to the ART regimen. No subjects switched their ART regimen due to loss of plasma HIV-1 RNA suppression.</p>
                     </text></div>
<span id="VIEKIRA_PAK_collapsableElement_14_7" class="safetySubheading">14.7 Durability of Response</span><div id="42229-5" class="safetySubdescription"><text>
                        <p id="p455999291415806375">In an open-label clinical trial, 92% of subjects (526/571) who received various combinations of the direct acting antivirals included in VIEKIRA PAK with or without RBV achieved SVR12, and 99% of those who achieved SVR12 maintained their response through 48 weeks post-treatment (SVR48).</p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34069-5">
<div class="drugSubheadings">
<span id="VIEKIRA_PAK_34069-5" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>16 HOW SUPPLIED/STORAGE AND HANDLING</div>
<div id="VIEKIRA_PAK_previewText_34069-5" class="previewText">
                  VIEKIRA PAK is dispensed in a monthly carton for a total of 2<span>...</span>
</div>
</div>
<div id="VIEKIRA_PAK_collapsableElement_34069-5" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"><text>
                  <p id="P34">VIEKIRA PAK is dispensed in a monthly carton for a total of 28 days of therapy. Each monthly carton contains four weekly cartons. Each weekly carton contains seven daily dose packs.</p>
                  <p id="p345690291394640508">Each child resistant daily dose pack contains four tablets: two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets and two 250 mg dasabuvir tablets, and indicates which tablets need to be taken in the morning and evening. The NDC number is NDC 0074-3093-28.</p>
                  <p id="p271847291394640520">Ombitasvir, paritaprevir, ritonavir 12.5/75/50 mg tablets are pink-colored, film-coated, oblong biconvex shaped, debossed with “AV1” on one side. Dasabuvir 250 mg tablets are beige-colored, film-coated, oval-shaped, debossed with “AV2” on one side.</p>
                  <p id="p396956291395946349">Store at or below 30°C (86°F).</p>
               </text></div></div>
</div>
<div class="section">
<div id="nonCollapsableElement_34076-0">
<div class="drugSubheadings">
<span id="VIEKIRA_PAK_34076-0" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>17  PATIENT COUNSELING INFORMATION</div>
<div id="VIEKIRA_PAK_previewText_34076-0" class="previewText">
                  Advise the patient to read the FDA-approved patient labeling <span>...</span>
</div>
</div>
<div id="VIEKIRA_PAK_collapsableElement_34076-0" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"><text>
                  <p id="P35">Advise the patient to read the FDA-approved patient labeling (<a href="#med_guide">Medication Guide</a>).</p>
                  <p id="p3332952321417656951">Inform patients to review the Medication Guide for ribavirin <content stylecode="italics">[see Warnings and Precautions (<a href="#section_5.3">5.3</a>)]</content>.</p>
                  <p id="p497122291413401109">
                     <content stylecode="underline">Risk of ALT Elevations or Hepatic Decompensation and Failure</content>
                  </p>
                  <p id="p499232291413401128">Inform patients to watch for early warning signs of liver inflammation or failure, such as fatigue, weakness, lack of appetite, nausea and vomiting, as well as later signs such as jaundice, onset of confusion, abdominal swelling, and discolored feces, and to consult their health care professional without delay if such symptoms occur <content stylecode="italics">[see Warnings and Precautions (<a href="#section_5.1">5.1</a> and <a href="#section_5.2">5.2</a>) and Adverse Reactions (<a href="#section_6">6</a>)]</content>.</p>
                  <p id="p345900291394640582">
                     <content stylecode="underline">Pregnancy</content>
                  </p>
                  <p id="p461147291416546848">Advise patients to avoid pregnancy during treatment with VIEKIRA PAK with ribavirin. Inform patients to notify their health care provider immediately in the event of a pregnancy. Inform pregnant patients that there is an Antiretroviral Pregnancy Registry that monitors pregnancy outcomes in women who are HCV/HIV-1 co-infected and taking concomitant antiretrovirals <content stylecode="italics">[see Use in Specific Populations (<a href="#section_8.1">8.1</a>)]</content>.</p>
                  <p id="p358616291394640732">
                     <content stylecode="underline">Drug Interactions</content>
                  </p>
                  <p id="p358595291394640744">Inform patients that VIEKIRA PAK may interact with some drugs; therefore, patients should be advised to report to their healthcare provider the use of any prescription, non-prescription medication or herbal products <content stylecode="italics">[see Contraindications (<a href="#section_4">4</a>), Warnings and Precautions (<a href="#section_5.4">5.4</a>) and Drug Interactions (<a href="#section_7">7</a>)]</content>.</p>
                  <p id="p3330632321417657270">Inform patients that contraceptives containing ethinyl estradiol are contraindicated with VIEKIRA PAK <content stylecode="italics">[see Contraindications (<a href="#section_4">4</a>) and Warnings and Precautions (<a href="#section_5.2">5.2</a>)]</content>.</p>
                  <p id="p358444291394640843">
                     <content stylecode="underline">Hepatitis C Virus Transmission</content>
                  </p>
                  <p id="p358675291394640864">Inform patients that the effect of treatment of hepatitis C virus infection on transmission is not known, and that appropriate precautions to prevent transmission of the hepatitis C virus during treatment should be taken.</p>
                  <p id="p358872291394640907">
                     <content stylecode="underline">Missed Dose</content>
                  </p>
                  <p id="p361002291394640916">Inform patients that in case a dose of ombitasvir, paritaprevir, ritonavir is missed, the prescribed dose can be taken within 12 hours.</p>
                  <p id="p361013291394640930">In case a dose of dasabuvir is missed, the prescribed dose can be taken within 6 hours.</p>
                  <p id="p361043291394640952">If more than 12 hours has passed since ombitasvir, paritaprevir, ritonavir is usually taken or more than 6 hours has passed since dasabuvir is usually taken, the missed dose should NOT be taken and the patient should take the next dose as per the usual dosing schedule.</p>
                  <p id="p340533291418223012">Instruct patients not to take more than their prescribed dose of VIEKIRA PAK to make up for a missed dose.</p>
                  <p id="p448214291418248914">Manufactured by AbbVie Inc., North Chicago, IL 60064.</p>
                  <p id="p517611291418248968">VIEKIRA PAK and NORVIR are trademarks of AbbVie Inc. All other brands uled are trademarks of their respective owners and are not trademarks of AbbVie Inc. The makers of these brands are not affiliated with and do not endorse AbbVie Inc. or its products.</p>
               </text></div></div>
</div>
<div class="section"><div id="VIEKIRA_PAK_collapsableElement_42229-5" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"><text>
                  <p id="p4636112291416520756">© 2015 AbbVie Inc. All rights reserved.</p>
                  <p id="p5071115291416520664">03-B243</p>
               </text></div></div></div>
<div class="section"><div id="VIEKIRA_PAK_collapsableElement_42231-1" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"><text>
                  <p id="p437974291396455961">
                     <content stylecode="bold">MEDICATION GUIDE</content>
                  </p>
                  <p id="p397225291395946728">
                     <content stylecode="bold">VIEKIRA PAK (vee-KEE-rah-pak)</content>
                  </p>
                  <p id="p3970610291395946753">
                     <content stylecode="bold">(ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets)</content>
                  </p>
                  <p id="p348526291414006507">
                     <content stylecode="bold">co-packaged for oral use</content>
                  </p>
                  <p id="p397105291395946790">Read this Medication Guide before you start taking VIEKIRA PAK and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment. You and your healthcare provider should talk about your treatment with VIEKIRA PAK before you start taking it and at regular check-ups. You should stay under your healthcare provider’s care when taking VIEKIRA PAK.</p>
                  <p id="p366084291418231546">
                     <content stylecode="bold">When taking VIEKIRA PAK in combination with ribavirin, you should also read the Medication Guide that comes with ribavirin.</content>
                  </p>
                  <p id="p399405291395946819">
                     <content stylecode="bold">What is the most important information I should know about VIEKIRA PAK?</content>
                  </p>
                  <ul ultype="unordered" id="l535361291444945826" stylecode="Disc">
                     <li>VIEKIRA PAK may cause severe liver problems, especially in people with certain types of cirrhosis. These severe liver problems can lead to the need for a liver transplant, or can lead to death.</li>
                     <li>VIEKIRA PAK can cause increases in your liver function blood test results, especially if you use ethinyl estradiol-containing medicines (such as some birth control products).<ul ultype="unordered" id="l535314291444945847" stylecode="Circle">
                           <li>You must stop using ethinyl estradiol-containing medicines before you start treatment with VIEKIRA PAK. See the section <content stylecode="bold">“Who should not take VIEKIRA PAK?”</content> for a ul of these medicines.</li>
                           <li>If you use these medicines as a method of birth control, you must use another method of birth control during treatment with VIEKIRA PAK, and for about <content stylecode="bold">2</content> weeks after you finish treatment with VIEKIRA PAK. Your healthcare provider will tell you when you may begin taking ethinyl estradiol-containing medicines.</li>
                        </ul>
                     </li>
                  </ul>
                  <ul ultype="unordered" id="l320231291395950030" stylecode="Disc">
                     <li>Your healthcare provider should do blood tests to check your liver function during the first 4 weeks and then as needed, during treatment with VIEKIRA PAK.</li>
                     <li>Your healthcare provider may tell you to stop taking VIEKIRA PAK if you develop signs or symptoms of liver problems.</li>
                     <li>Tell your healthcare provider right away if you develop any of the following symptoms, or if they worsen during treatment with VIEKIRA PAK:<ul ultype="unordered" id="l481416291418241453" stylecode="Disc">
                           <li>tiredness</li>
                           <li>weakness</li>
                           <li>loss of appetite</li>
                           <li>nausea and vomiting</li>
                           <li>yellowing of your skin or eyes</li>
                           <li>color changes in your stools</li>
                           <li>confusion</li>
                           <li>swelling of the stomach area</li>
                        </ul>
                     </li>
                  </ul>
                  <p id="p3994310291395947090">
                     <content stylecode="bold">What is VIEKIRA PAK?</content>
                  </p>
                  <p id="p401955291395947103">VIEKIRA PAK is a prescription medicine used with or without ribavirin to treat people with genotype 1 chronic (lasting a long time) hepatitis C virus (HCV) infection, including people who have a certain type of cirrhosis (compensated).</p>
                  <p id="p401966291395947108">VIEKIRA PAK is not for people with advanced cirrhosis (decompensated). If you have cirrhosis, talk to your healthcare provider before taking VIEKIRA PAK.</p>
                  <p id="p401996291395947125">VIEKIRA PAK contains 2 different types of tablets. <content stylecode="bold">You must take both types of tablets</content> exactly as prescribed, to treat your chronic hepatitis C virus (HCV) infection.</p>
                  <ul ultype="unordered" id="l366486291418241638" stylecode="Disc">
                     <li>the pink tablet contains: the medicines ombitasvir, paritaprevir, and ritonavir</li>
                     <li>the beige tablet contains: the medicine dasabuvir</li>
                  </ul>
                  <p id="p519927291418842886">If you take VIEKIRA PAK with ribavirin, you should also read the Medication Guide for ribavirin.</p>
                  <p id="p532793291418241696">It is not known if VIEKIRA PAK is safe and effective in children under 18 years of age.</p>
                  <p id="p402026291395947144">
                     <content stylecode="bold">Who should not take VIEKIRA PAK?</content>
                  </p>
                  <p id="p440354291414006891">
                     <content stylecode="bold">Do not take VIEKIRA PAK if you:</content>
                  </p>
                  <ul ultype="unordered" id="l532891291418241733" stylecode="Disc">
                     <li>
                        <content stylecode="bold">have certain liver problems</content>
                     </li>
                     <li>
                        <content stylecode="bold">take any of the following medicines:</content>
                        <ul ultype="unordered" id="l535153291418241762" stylecode="Disc">
                           <li>alfuzosin hydrochloride (Uroxatral<sup>®</sup>)</li>
                           <li>carbamazepine (Carbatrol<sup>®</sup>, Epitol<sup>®</sup>, Equetro<sup>®</sup>, Tegretol<sup>®</sup>)</li>
                           <li>colchicine (Colcrys<sup>®</sup>)</li>
                           <li>efavirenz (Atripla<sup>®</sup>, Sustiva<sup>®</sup>)</li>
                           <li>ergot containing medicines including:<ul ultype="unordered" id="l537753291418241856" stylecode="Circle">
                                 <li>ergotamine tartrate (Cafergot<sup>®</sup>, Ergomar<sup>®</sup>, Ergostat<sup>®</sup>, Medihaler<sup>®</sup>, Migergot<sup>®</sup>, Wigraine<sup>®</sup>, Wigrettes<sup>®</sup>)</li>
                                 <li>dihydroergotamine mesylate (D.H.E. 45<sup>®</sup>, Migranal<sup>®</sup>)</li>
                                 <li>methylergonovine (Ergotrate<sup>®</sup>, Methergine<sup>®</sup>)</li>
                              </ul>
                           </li>
                           <li>ethinyl estradiol-containing medicines:<ul ultype="unordered" id="l542932291418242007" stylecode="Circle">
                                 <li>combination birth control pills or patches, such as Lo Loestrin<sup>®</sup> FE, Norinyl<sup>®</sup>, Ortho Tri-Cyclen Lo<sup>®</sup>, Ortho Evra<sup>® </sup>
                                 </li>
                                 <li>hormonal vaginal rings such as NuvaRing<sup>®</sup>
                                 </li>
                                 <li>the hormone replacement therapy medicine, Fem HRT<sup>®</sup>
                                 </li>
                              </ul>
                           </li>
                           <li>gemfibrozil (Lopid<sup>®</sup>)</li>
                           <li>lovastatin (Advicor<sup>®</sup>, Altoprev<sup>®</sup>, Mevacor<sup>®</sup>)</li>
                           <li>midazolam, when taken by mouth</li>
                           <li>phenytoin, (Dilantin<sup>®</sup>, Phenytek<sup>®</sup>)</li>
                           <li>phenobarbital (Luminal<sup>®</sup>)</li>
                           <li>pimozide (Orap<sup>®</sup>)</li>
                           <li>rifampin (Rifadin<sup>®</sup>, Rifamate<sup>®</sup>, Rifater<sup>®</sup> Rimactane<sup>®</sup>)</li>
                           <li>sildenafil citrate (Revatio<sup>®</sup>), when taken for pulmonary artery hypertension (PAH)</li>
                           <li>simvastatin (Simcor<sup>®</sup>, Vytorin<sup>®</sup>, Zocor<sup>®</sup>)</li>
                           <li>St. John’s wort (Hypericum perforatum) or a product that contains St. John’s wort </li>
                           <li>triazolam (Halcion<sup>®</sup>)</li>
                        </ul>
                     </li>
                     <li>
                        <content stylecode="bold">have had a severe skin rash after taking ritonavir (Norvir<sup>®</sup>).</content>
                     </li>
                  </ul>
                  <p id="p476561408-EC237A52">
                     <content stylecode="bold">What should I tell my healthcare provider before taking VIEKIRA PAK?</content>
                  </p>
                  <p id="p440692291414006970">
                     <content stylecode="bold">Tell your healthcare provider about all your medical conditions, including if you:</content>
                  </p>
                  <ul ultype="unordered" id="l363851291414012353" stylecode="Disc">
                     <li>have liver problems other than hepatitis C infection. <content stylecode="bold">See “Who should not take VIEKIRA PAK?”</content>
                     </li>
                     <li>have HIV infection</li>
                     <li>have had a liver transplant. If you take the medicines tacrolimus (Prograf<sup>®</sup>) or cyclosporine (Gengraf<sup>®</sup>, Neoral<sup>®</sup>, Sandimmune<sup>®</sup>) to help prevent rejection of your transplanted liver, the amount of these medicines in your blood may increase during treatment with VIEKIRA PAK.<ul ultype="unordered" id="l507021291414007629" stylecode="Circle">
                           <li>Your healthcare provider should check the level of tacrolimus or cyclosporine in your blood, and if needed may change your dose of these medicines or how often you take them.</li>
                           <li>When you finish taking VIEKIRA PAK or if you have to stop VIEKIRA PAK for any reason, your healthcare provider should tell you what dose of tacrolimus or cyclosporine you should take and how often you should take it.</li>
                        </ul>
                     </li>
                     <li>have any other medical conditions</li>
                     <li>are pregnant or plan to become pregnant. It is not known if VIEKIRA PAK will harm your unborn baby. <content stylecode="bold">When taking VIEKIRA PAK in combination with ribavirin you should also read the ribavirin Medication Guide for important pregnancy information.</content>
                        <p id="p5453311291418242769">
                           <content stylecode="bold">Pregnancy Registry: </content>There is a registry for females who take antiretroviral medicines during pregnancy. The purpose of this registry is to collect information about the health of the pregnant mother and her baby. If you are a pregnant female and have both HCV and HIV infection, talk with your healthcare provider about enrolling in this registry.</p>
                     </li>
                     <li>are breastfeeding or plan to breastfeed.  It is not known if VIEKIRA PAK passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take VIEKIRA PAK.</li>
                  </ul>
                  <p id="p407184291395947272">
                     <content stylecode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines interact with VIEKIRA PAK. <content stylecode="bold">Keep a ul of your medicines to show your healthcare provider and pharmacist.</content>
                  </p>
                  <ul ultype="unordered" id="l532721291418242880" stylecode="Disc">
                     <li>You can ask your healthcare provider or pharmacist for a ul of medicines that interact with VIEKIRA PAK.</li>
                     <li>
                        <content stylecode="bold">Do not start taking a new medicine without telling your healthcare provider. </content>Your healthcare provider can tell you if it is safe to take VIEKIRA PAK with other medicines.</li>
                     <li>When you finish treatment with VIEKIRA PAK:<ul ultype="unordered" id="l502014291418843293" stylecode="Circle">
                           <li>If your healthcare provider changed the dose of any of your usual medicines during treatment with VIEKIRA PAK: Ask your healthcare provider about when you should change back to your original dose after you finish treatment with VIEKIRA PAK.</li>
                           <li>If your healthcare provider told you to stop taking any of your usual medicines during treatment with VIEKIRA PAK: Ask your healthcare provider if you should start taking these medicines again after you finish treatment with VIEKIRA PAK.</li>
                        </ul>
                     </li>
                  </ul>
                  <p id="p442998291395947837">
                     <content stylecode="bold">How should I take VIEKIRA PAK?</content>
                  </p>
                  <ul ultype="unordered" id="l442914291395947847" stylecode="Disc">
                     <li>Take VIEKIRA PAK exactly as your healthcare provider tells you to take it. Do not change your dose unless your healthcare provider tells you to.</li>
                     <li>Do not stop taking VIEKIRA PAK without first talking with your healthcare provider.</li>
                     <li>When you receive your VIEKIRA PAK prescription, you will get a <content stylecode="bold">monthly carton that contains enough medicine for 28 days</content>.</li>
                     <li>Each monthly carton of VIEKIRA PAK contains <content stylecode="bold">4 smaller cartons</content>.</li>
                     <li>Each of the 4 smaller cartons contains enough child resistant <content stylecode="bold">daily dose packs</content> of medicine to last for <content stylecode="bold">7 days</content> (1 week).</li>
                     <li>Each <content stylecode="bold">daily dose pack</content> contains all of your VIEKIRA PAK medicine for <content stylecode="bold">1 day</content> (4 tablets).  Follow the instructions on each daily dose pack about how to remove the tablets.</li>
                     <li>Take VIEKIRA PAK tablets with a meal as follows: <ul ultype="unordered" id="l443217291396019377" stylecode="Circle">
                           <li>take the <content stylecode="bold">2 </content>pink tablets (ombitasvir, paritaprevir, and ritonavir), with <content stylecode="bold">1</content> of the beige tablets (dasabuvir), at about the same time every morning.</li>
                           <li>take the <content stylecode="bold">second</content> beige tablet (dasabuvir), at about the same time every evening.</li>
                        </ul>
                     </li>
                     <li>If you miss a dose of the pink tablets, and it is <content stylecode="bold">less than 12 hours</content> from the time you usually take your dose, <content stylecode="bold">take the missed dose</content> with a meal as soon as possible. Then take your next dose at your usual time with a meal.</li>
                     <li>If you miss a dose of the pink tablets, and it is <content stylecode="bold">more than 12 hours</content> from the time you usually take your dose, <content stylecode="bold">do not take the missed dose</content>. Take your next dose at your usual time with a meal.</li>
                     <li>If you miss a dose of the beige tablet, and it is <content stylecode="bold">less than 6 hours</content> from the time you usually take your dose, <content stylecode="bold">take the missed dose </content>with a meal as soon as possible. Then take your next dose at your usual time with a meal.</li>
                     <li>If you miss a dose of the beige tablet, and it is <content stylecode="bold">more than 6 hours </content>from the time you usually take your dose, <content stylecode="bold">do not take the missed dose</content>. Take your next dose at your usual time with a meal.</li>
                     <li>Do not take more than your prescribed dose of VIEKIRA PAK to make up for a missed dose.</li>
                     <li>If you take too much VIEKIRA PAK, call your healthcare provider or go to the nearest emergency room right away.</li>
                  </ul>
                  <p id="p4815214291414008645">
                     <content stylecode="bold">What are the possible side effects of VIEKIRA PAK?</content>
                  </p>
                  <p id="p399744291418243541">See <content stylecode="bold">“What is the most important information I should know about VIEKIRA PAK?”</content>
                  </p>
                  <p id="p43550122551396051785">
                     <content stylecode="bold">Common side effects of VIEKIRA PAK when used with ribavirin include:</content>
                  </p>
                  <ul ultype="unordered" id="l4356282551396051742" stylecode="Disc">
                     <li>tiredness</li>
                     <li>nausea</li>
                     <li>itching</li>
                     <li>skin reactions such as redness or rash</li>
                     <li>sleep problems</li>
                     <li>feeling weak</li>
                  </ul>
                  <p id="p5196911291418243673">
                     <content stylecode="bold">Common side effects of VIEKIRA PAK when used without ribavirin include:</content>
                  </p>
                  <ul ultype="unordered" id="l5226012291418243689" stylecode="Disc">
                     <li>nausea</li>
                     <li>itching</li>
                     <li>sleep problems</li>
                  </ul>
                  <p id="p463604291395948527">Tell your healthcare provider about any side effect that bothers you or that does not go away.</p>
                  <p id="p463622291395948539">These are not all the possible side effects of VIEKIRA PAK. For more information, ask your healthcare provider or pharmacist.</p>
                  <p id="p463652291395948547">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
                  <p id="p463682291395948558">
                     <content stylecode="bold">How should I store VIEKIRA PAK?</content>
                  </p>
                  <ul ultype="unordered" id="l4817610291418243764" stylecode="Disc">
                     <li>Store VIEKIRA PAK at or below 86°F (30°C).</li>
                  </ul>
                  <p id="p4557313291395948651">
                     <content stylecode="bold">Keep VIEKIRA PAK and all medicines out of the reach of children.</content>
                  </p>
                  <p id="p463775291395948667">
                     <content stylecode="bold">General information about the safe and effective use of VIEKIRA PAK</content>
                  </p>
                  <p id="p465959291395948691">It is not known if treatment with VIEKIRA PAK will prevent you from infecting another person with the hepatitis C virus during your treatment. Talk with your healthcare provider about ways to prevent spreading the hepatitis C virus.</p>
                  <p id="p451036291414008765">Medicines are sometimes prescribed for purposes other than those uled in a Medication Guide. Do not use VIEKIRA PAK for a condition for which it was not prescribed. Do not give VIEKIRA PAK to other people, even if they have the same condition you have. It may harm them.</p>
                  <p id="p3789311291414008811">If you would like more information about VIEKIRA PAK, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about VIEKIRA PAK that is written for health professionals.</p>
                  <p id="p402345291418243880">For more information, call 1-800-633-9110 or go to www.viekira.com.</p>
                  <p id="p466049291395948749">
                     <content stylecode="bold">What are the ingredients in VIEKIRA PAK?</content>
                  </p>
                  <p id="p466079291395948761">
                     <content stylecode="bold">Ombitasvir, paritaprevir, and ritonavir tablets:</content>
                  </p>
                  <p id="p466129291395948766">
                     <content stylecode="bold">Active ingredients:</content> ombitasvir, paritaprevir, and ritonavir</p>
                  <p id="p466179291395948785">
                     <content stylecode="bold">Inactive ingredients:</content> copovidone, K value 28, vitamin E polyethylene glycol succinate, propylene glycol monolaurate Type I, sorbitan monolaurate, colloidal silicon dioxide/colloidal anhydrous silica, sodium stearyl fumarate, polyvinyl alcohol, polyethylene glycol 3350/macrogol 3350, talc, titanium dioxide, and red iron oxide.</p>
                  <p id="p466239291395948795">
                     <content stylecode="bold">Dasabuvir tablets:</content>
                  </p>
                  <p id="p466299291395948804">
                     <content stylecode="bold">Active ingredients:</content> dasabuvir</p>
                  <p id="p466349291395948809">
                     <content stylecode="bold">Inactive ingredients:</content> microcrystalline cellulose (D50-100 um), microcrystalline cellulose (D50-50 um), lactose monohydrate, copovidone, croscarmellose sodium, colloidal silicon dioxide/anhydrous colloidal silica, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol 3350/macrogol 3350, talc and iron oxide yellow, iron oxide red and iron oxide black.</p>
                  <p id="p384283291414013090">This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
                  <br>
                  <p id="p468523291395948856">Manufactured by AbbVie Inc., North Chicago, IL 60064.</p>
               </text></div></div></div>
<div class="section"><div id="VIEKIRA_PAK_collapsableElement_42229-5" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"><text>
                  <p id="p363943291418752989">Revised: October 2015</p>
                  <p id="p517149291418250636">VIEKIRA PAK and NORVIR are trademarks of AbbVie Inc. All other brands uled are trademarks of their respective owners and are not trademarks of AbbVie Inc. The makers of these brands are not affiliated with and do not endorse AbbVie Inc. or its products.</p>
                  <p id="p5072011291416520930">© 2015 AbbVie Inc. All rights reserved.</p>
                  <p id="p5072111291416520925">03-B243</p>
               </text></div></div></div>
<div class="section"></div>
</div>